0001213900-19-015804.txt : 20190814 0001213900-19-015804.hdr.sgml : 20190814 20190814161309 ACCESSION NUMBER: 0001213900-19-015804 CONFORMED SUBMISSION TYPE: 10-Q PUBLIC DOCUMENT COUNT: 41 CONFORMED PERIOD OF REPORT: 20190630 FILED AS OF DATE: 20190814 DATE AS OF CHANGE: 20190814 FILER: COMPANY DATA: COMPANY CONFORMED NAME: Hoth Therapeutics, Inc. CENTRAL INDEX KEY: 0001711786 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 821553794 STATE OF INCORPORATION: NV FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 10-Q SEC ACT: 1934 Act SEC FILE NUMBER: 001-38803 FILM NUMBER: 191026498 BUSINESS ADDRESS: STREET 1: 1 ROCKEFELLER PLAZA, SUITE 1039 CITY: NEW YORK STATE: NY ZIP: 10020 BUSINESS PHONE: 551-578-2261 MAIL ADDRESS: STREET 1: 1 ROCKEFELLER PLAZA, SUITE 1039 CITY: NEW YORK STATE: NY ZIP: 10020 10-Q 1 f10q0619_hoththerapeutics.htm QUARTERLY REPORT

 

 

 UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, DC 20549

 

FORM 10-Q 

 

(Mark One)

☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

 

For the quarterly period ended June 30, 2019

 

OR

 

☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

 

For the transition period from ________________ to ________________

 

Commission File Number: 001-38803

 

Hoth Therapeutics, Inc.

(Exact Name of Registrant as Specified in its Charter) 

 

Nevada   82-1553794
(State or other jurisdiction of
incorporation or organization)		   (I.R.S. Employer
Identification No.)
     
1 Rockefeller Plaza, Suite 1039    
New York, NY   10020
(Address of principal executive offices)   (Zip Code)

 

(646) 756-2997

(Registrant’s telephone number, including area code)

 

Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days. Yes ☒  No ☐

 

Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T (§ 232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit such files). Yes ☒ No ☐

 

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company or an emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer,” “smaller reporting company,” and “emerging growth company” in Rule 12b-2 of the Exchange Act.

 

Large accelerated filer ☐   Accelerated filer ☐
Non-accelerated filer ☒   Smaller reporting company ☒
      Emerging growth company ☒

 

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 7(a)(2)(B) of the Securities Act. ☐

 

Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act). Yes ☐ No ☒

 

Securities registered pursuant to Section 12(b) of the Act:

 

Title of each class   Trading symbol(s)   Name of each exchange on which registered
Common Stock, $0.0001 par value   HOTH   The Nasdaq Stock Market LLC

 

The number of shares of the issuer’s common stock, $0.0001 par value per share, outstanding at August 13, 2019 was 9,669,644.

   

 

 

 

 

Table of Contents

 

   

Page No.

Part I. Financial Information 1
     
Item 1. Financial Statements 1
     
  Condensed Balance Sheets as of June 30, 2019 (Unaudited) and December 31, 2018 1
     
  Condensed Statements of Operations for the three and six months ended June 30, 2019 and 2018 (Unaudited) 2
     
  Condensed Statements of Changes in Stockholders’ Equity for the three and six months ended June 30, 2019 and 2018 (Unaudited) 3
     
  Condensed Statements of Cash Flows for the six months ended June 30, 2019 and 2018 (Unaudited) 4
     
  Notes to the Condensed Financial Statements (Unaudited) 5
     
Item 2. Management’s Discussion and Analysis of Financial Condition and Results of Operations 10
     
Item 3. Quantitative and Qualitative Disclosures About Market Risk 14
     
Item 4. Controls and Procedures 14
     
Part II. Other Information 15
     
Item 1. Legal Proceedings 15
     
Item 1A. Risk Factors 15
     
Item 2. Unregistered Sales of Equity Securities and Use of Proceeds 15
     
Item 3. Defaults Upon Senior Securities 15
     
Item 4. Mine Safety Disclosures 15
     
Item 5. Other Information 15
     
Item 6. Exhibits 16
     
Signatures 17

  

i

 

 

 CAUTIONARY NOTE REGARDING FORWARD-LOOKING STATEMENTS AND INDUSTRY DATA

 

This Quarterly Report on Form 10-Q contains forward-looking statements which are made pursuant to the safe harbor provisions of Section 27A of the Securities Act of 1933, as amended (the “Securities Act”), and Section 21E of the Securities Exchange Act of 1934, as amended (the “Exchange Act”). These statements may be identified by such forward-looking terminology as “may,” “should,” “expects,” “intends,” “plans,” “anticipates,” “believes,” “estimates,” “predicts,” “potential,” “continue” or the negative of these terms or other comparable terminology. Our forward-looking statements are based on a series of expectations, assumptions, estimates and projections about our company, are not guarantees of future results or performance and involve substantial risks and uncertainty. We may not actually achieve the plans, intentions or expectations disclosed in these forward-looking statements. Actual results or events could differ materially from the plans, intentions and expectations disclosed in these forward-looking statements. Our business and our forward-looking statements involve substantial known and unknown risks and uncertainties, including the risks and uncertainties inherent in our statements regarding:

 

  ● our business strategies;

  

  ● the timing of regulatory submissions;

  

  ● our ability to obtain and maintain regulatory approval of our existing product candidates and any other product candidates we may develop, and the labeling under any approval we may obtain;

  

  ● risks relating to the timing and costs of clinical trials, the timing and costs of other expenses;

  

  ● risks related to market acceptance of products;

  

  ● intellectual property risks;

  

  ● risks associated with our reliance on third party organizations;

  

  ● our competitive position;

  

  ● our industry environment;

  

  ● our anticipated financial and operating results, including anticipated sources of revenues;

  

  ● assumptions regarding the size of the available market, benefits of our products, product pricing, timing of product launches;

  

  ● management’s expectation with respect to future acquisitions;

  

  ● statements regarding our goals, intensions, plans and expectations, including the introduction of new products and markets; and

  

  ● our cash needs and financing plans.

 

All of our forward-looking statements are as of the date of this Quarterly Report on Form 10-Q only. In each case, actual results may differ materially from such forward-looking information. We can give no assurance that such expectations or forward-looking statements will prove to be correct. An occurrence of, or any material adverse change in, one or more of the risk factors or risks and uncertainties referred to in this Quarterly Report on Form 10-Q or included in our other public disclosures or our other periodic reports or other documents or filings filed with or furnished to the U.S. Securities and Exchange Commission (the “SEC”) could materially and adversely affect our business, prospects, financial condition and results of operations. Except as required by law, we do not undertake or plan to update or revise any such forward-looking statements to reflect actual results, changes in plans, assumptions, estimates or projections or other circumstances affecting such forward-looking statements occurring after the date of this Quarterly Report on Form 10-Q, even if such results, changes or circumstances make it clear that any forward-looking information will not be realized. Any public statements or disclosures by us following this Quarterly Report on Form 10-Q that modify or impact any of the forward-looking statements contained in this Quarterly Report on Form 10-Q will be deemed to modify or supersede such statements in this Quarterly Report on Form 10-Q.

 

This Quarterly Report on Form 10-Q may include market data and certain industry data and forecasts, which we may obtain from internal company surveys, market research, consultant surveys, publicly available information, reports of governmental agencies and industry publications, articles and surveys. Industry surveys, publications, consultant surveys and forecasts generally state that the information contained therein has been obtained from sources believed to be reliable, but the accuracy and completeness of such information is not guaranteed. While we believe that such studies and publications are reliable, we have not independently verified market and industry data from third-party sources.

  

ii

 

 

PART I — FINANCIAL INFORMATION

 

ITEM 1.FINANCIAL STATEMENTS.

 

Hoth Therapeutics, Inc.

Condensed Balance Sheets

  

   June 30   December 31 
   2019   2018 
   (Unaudited)     
ASSETS        
Current assets        
Cash  $4,092,706   $282,621 
Prepaid expenses   101,320    12,356 
Deferred offering cost   32,127    206,671 
Total current assets   4,226,153    501,648 
           
Property and equipment, net   1,660    2,268 
Restricted cash   200,000    - 
Total assets  $4,427,813   $503,916 
           
LIABILITIES AND STOCKHOLDERS’ EQUITY          
Current liabilities          
Accounts payable  $212,266   $142,280 
Accrued expenses   27,127    206,671 
Total current liabilities   239,393    348,951 
           
Total liabilities   239,393    348,951 
           
Commitments and contingencies          
           
Stockholders’ equity          
Preferred stock, $0.0001 par value, 5,000,000 shares authorized at June 30, 2019 and December 31, 2018; 0 shares issued and outstanding at June 30, 2019 and December 31, 2018   -    - 
Series A Preferred Stock, $0.0001 par value, 5,000,000 shares authorized at June 30, 2019 and December 31, 2018; 0 and 3,102,480 shares issued and outstanding at June 30, 2019 and December 31, 2018, respectively   -    310 
Common stock, 0.0001 par value, 75,000,000 shares authorized at June 30, 2019 and December 31, 2018; 9,668,256 and 5,071,400 shares issued and outstanding at June 30, 2019 and December 31, 2018, respectively   967    507 
Additional paid-in-capital   10,795,410    4,665,154 
Accumulated deficit   (6,607,957)   (4,511,006)
Total stockholders’ equity   4,188,420    154,965 
Total liabilities and stockholders’ equity  $4,427,813   $503,916 

 

 The accompanying notes are an integral part of these unaudited financial statements.

   

1

 

 

Hoth Therapeutics, Inc.

Condensed Statements of Operations

(Unaudited)

  

   Three Months Ended
June 30,		   Six Months Ended
June 30,		 
   2019   2018   2019   2018 
                 
Operating costs and expenses                
Research and development  $388,934   $216,667   $523,684   $257,907 
Research and development - license acquired   10,000    32,028    20,000    164,192 
Compensation and related expenses (including stock-based compensation)   133,486    210,453    454,935    319,482 
Professional fees   544,849    229,899    838,364    422,159 
Rent   8,234    6,300    15,263    12,439 
Other expenses   182,083    68,073    244,705    114,787 
Total operating expenses   1,267,586    763,420    2,096,951    1,290,966 
Loss from operations   (1,267,586)   (763,420)   (2,096,951)   (1,290,966)
                     
Net loss  $(1,267,586)  $(763,420)  $(2,096,951)  $(1,290,966)
                     
Weighted average number of common shares outstanding, basic and diluted   9,603,134    5,039,800    8,312,327    4,986,306 
                     
Net loss per share, basic and diluted  $(0.13)  $(0.15)  $(0.25)  $(0.26)

  

The accompanying notes are an integral part of these unaudited financial statements.

 

2

 

  

Hoth Therapeutics, Inc.

Condensed Statements of Changes in Stockholders’ Equity

(Unaudited)

 

For the Three Months Ended June 30, 2019

  

   Convertible
Preferred Stock		   Common Stock   Additional  Paid-in   Accumulated   Total Stockholders’ 
   Shares   Amount   Shares   Amount   Capital   Deficit   Equity 
Balance at March 31, 2019         -   $         -    9,425,964   $943   $10,707,905   $(5,340,371)  $5,368,477 
Cashless warrant exercise             223,877    22    (22)   -    - 
Warrant exercise             16,333    2    161    -    163 
Stock-based compensation   -    -    2,082    -    87,366    -    87,366 
Net loss   -    -    -    -    -    (1,267,586)   (1,267,586)
Balance at June 30, 2019   -   $-    9,668,256   $967   $10,795,410   $(6,607,957)  $4,188,420 

  

For the Three Months Ended June 30, 2018  

  

   Convertible
Preferred Stock		   Common Stock   Additional Paid-in   Accumulated   Total Stockholders’ 
   Shares   Amount   Shares   Amount   Capital   Deficit   Equity 
Balance at March 31, 2018   3,102,480   $310    4,956,943   $496   $4,543,626   $(2,543,027)  $2,001,405 
Stock-based compensation          -            -    117,500    11    117,489    -    117,500 
Stock issued for research and development   -    -    12,500    1    12,499    -    12,500 
Net loss   -    -    -    -    -    (763,420)   (763,420)
Balance at June 30, 2018   3,102,480   $ 310    5,086,943   $508   $4,673,614   $(3,306,447)  $1,367,985 

 

For the Six Months Ended June 30, 2019

  

   Convertible
Preferred Stock		   Common Stock   Additional Paid-in   Accumulated   Total Stockholders’ 
   Shares   Amount   Shares   Amount   Capital   Deficit   Equity 
Balance at December 31, 2018   3,102,480   $310    5,071,400   $507   $4,665,154   $(4,511,006)  $154,965 
Conversion of preferred stock to common stock upon completion of the IPO   (3,102,480)   (310)   3,102,480    310    -    -    - 
Issuance common stock in the IPO, net of offering cost   -    -    1,250,000    126    5,840,042    -    5,840,168 
Cashless warrant exercise   -    -    223,877    22    (22)   -    - 
Warrant exercise             16,333    2    161    -    163 
Stock-based compensation   -    -    4,166    -    290,075    -    290,075 
Net loss   -    -    -    -    -    (2,096,951)   (2,096,951)
Balance at June 30, 2019   -   $-    9,668,256   $967   $10,795,410   $(6,607,957)  $4,188,420 

 

For the Six Months Ended June 30, 2018

  

   Convertible
Preferred Stock		   Common Stock   Additional Paid-in   Accumulated   Total Stockholders’ 
   Shares   Amount   Shares   Amount   Capital   Deficit   Equity 
Balance at December 31, 2017   1,725,980   $173    4,706,277   $470   $3,199,304   $(2,015,481)  $1,184,466 
Issuance of Series A Convertible Preferred Stock and warrants for cash in an offering (net of offering costs of $190,180)   1,376,500    137    -    -    1,021,417    -    1,021,554 
Warrant value related to Issuance of Series A Convertible Preferred Stock   -    -    -    -    164,767    -    164,767 
Stock-based compensation   -    -    142,500    14    132,486    -    132,500 
Stock issued for research and development   -    -    25,000    3    23,497    -    23,500 
Stock issued for acquired license   -    -    213,166    21    132,143    -    132,164 
Net loss   -    -    -    -    -    (1,290,966)   (1,290,966)
Balance at June 30, 2018   3,102,480   $ 310    5,086,943   $508   $4,673,614   $(3,306,447)  $1,367,985 

  

The accompanying notes are an integral part of these unaudited financial statements.

  

3

 

  

Hoth Therapeutics, Inc.

Condensed Statements of Cash Flows

 (Unaudited)

  

   Six Months Ended
June 30,		 
   2019   2018 
Cash flows from operating activities        
Net loss  $(2,096,951)  $(1,290,966)
Adjustments to reconcile net loss to net cash used in operating activities:          
Depreciation expense   608    607 
Research and development-acquired license, expensed   20,000    132,164 
Stock issued for research and development   -    23,500 
Stock-based compensation   290,075    132,500 
Changes in assets and liabilities:          
Prepaid expenses   (88,964)   (27,184)
Accrued salaries and benefits   -    (1,542)
Accounts payable   64,986    80,984 
Net cash used in operating activities   (1,810,246)   (949,937)
           
Cash flows from investing activities          
Purchase of research and development licenses   (20,000)   - 
Net cash used in investing activities   (20,000)   - 
           
Cash flows from financing activities          
Proceeds from issuance of Series A Convertible Preferred Stock and warrants for cash in an offering, net   -    1,186,321 
Cash from issuance of common stock in the IPO, net of offering cost   5,840,168    - 
Proceeds from exercise of warrants   163    - 
Net cash provided by financing activities   5,840,331    1,186,321 
           
Net increase in cash   4,010,085    236,384 
Cash and restricted cash, beginning of period   282,621    1,230,440 
           
Cash and restricted cash, end of period  $4,292,706   $1,466,824 
           
Non-cash investing and financing activities          
Conversion of preferred stock to common stock upon completion of the IPO  $310   $- 
Common stock issued for acquired license       $132,164 
Cashless warrant exercise  $22   $- 
Unpaid offering cost included in accrued expenses  $27,127   $- 

  

The accompanying notes are an integral part of these unaudited financial statements.

  

4

 

  

Hoth Therapeutics, Inc.

Notes to Condensed Financial Statements  

(Unaudited)

 

Note 1-Organization and description of business operations

 

Hoth Therapeutics, Inc. (the “Company”) was incorporated under the laws of the State of Nevada on May 16, 2017. The Company’s primary asset is a sublicense agreement with Chelexa Biosciences, Inc. (“Chelexa”) pursuant to which Chelexa has granted the Company an exclusive sublicense to use its BioLexa Platform, a proprietary, patented, drug compound platform developed at the University of Cincinnati. The license enables the Company to develop the platform for all indications in humans. The Company’s initial focus will be on the treatment of eczema. The BioLexa Platform combines a U.S. Food and Drug Administration (“FDA”) approved zinc chelator with one or more approved antibiotics in a topical dosage form to address unchecked eczema flare-ups by preventing the formation of infectious biofilms and the resulting clogging of sweat ducts which trigger symptoms. To the Company’s knowledge, it is the first product candidate intended to prevent the symptom triggering flare-ups rather than simply treating symptoms when they occur.

 

On May 26, 2017, the Company entered into a sublicense agreement with Chelexa, as amended on August 22, 2018 and August 29, 2018, pursuant to which Chelexa granted the Company an exclusive sublicense to make, use, have made, import, offer for sale, and sell products based upon or involving the use of (i) topical compositions comprising a zinc chelator and gentamicin and (ii) zinc chelators to inhibit biofilm formation (the “BioLexa Platform” or “BioLexa”), which rights were originally granted to Chelexa pursuant to an exclusive license agreement with the University of Cincinnati. In addition, Chelexa granted the Company the right to issue exclusive and nonexclusive sublicenses (with the right to further sublicense to third parties) to make, use, have made, import, offer for sale, and sell products based upon the BioLexa Platform.

 

Company’s IPO

 

On February 15, 2019, the Company announced the pricing of its initial public offering (the “IPO”) of 1,250,000 shares of its common stock at an initial offering price to the public of $5.60 per share.  In addition, the Company granted the underwriters a 45-day option to purchase up to an additional 187,500 shares of common stock at the initial public offering price, less the underwriting discount, to cover over-allotments (the “Green-shoe”), if any. The underwriters did not exercise any portion of the Green-shoe. Therefore, the Company issued 1,250,000 shares of common stock and received net proceeds of $5.8 million from the IPO.

 

The Company’s common stock commenced trading on The Nasdaq Capital Market, on February 15, 2019 under the ticker symbol “HOTH”. The IPO closed on February 20, 2019.

 

On February 14, 2019, the Company entered into an underwriting agreement with Laidlaw & Co. (UK) Ltd. (“Laidlaw”) pursuant to which the Company paid Laidlaw a fee in the amount of 7% of the gross proceeds of the IPO, or $490,000. The Company also reimbursed Laidlaw for certain out-of-pocket expenses, including the fees and disbursements of their counsel, up to an aggregate of $0.2 million. In addition, Laidlaw received five-year warrants to purchase 50,000 shares of common stock of the Company at an exercise price of $7.00 per share.

 

Liquidity and capital resources

 

Accounting Standards Update, or ASU, No. 2014-15, Presentation of Financial Statements - Going Concern, requires management to evaluate the Company’s ability to continue as a going concern one year beyond the filing date of the given financial statements. This evaluation requires management to perform two steps. First, management must evaluate whether there are conditions and events that raise substantial doubt about the entity’s ability to continue as a going concern. Second, if management concludes that substantial doubt is raised, management is required to consider whether it has plans in place to alleviate that doubt. Disclosures in the notes to the financial statements are required if management concludes that substantial doubt exists or that its plans alleviate the substantial doubt that was raised.

 

The Company has incurred substantial operating losses since inception and expects to continue to incur significant operating losses for the foreseeable future and may never become profitable. As of June 30, 2019, the Company had cash of approximately $4.1 million, working capital of approximately $4.0 million and an accumulated deficit of approximately $6.6 million.

 

The Company has funded its operations from proceeds from the sale of equity and debt securities. The Company will require significant additional capital to make the investments it needs to execute its longer-term business plan. The Company’s ability to successfully raise sufficient funds through the sale of debt or equity securities when needed is subject to many risks and uncertainties and, even if it were successful, future equity issuances would result in dilution to its existing stockholders and any future debt securities may contain covenants that limit the Company’s operations or ability to enter into certain transactions.

 

The proceeds from the IPO and the current cash are sufficient to fund operations for at least the next 12 months; however, the Company will need to raise additional funding through strategic relationships, public or private equity or debt financings, grants or other arrangements to develop and seek regulatory approvals for the Company’s existing and new product candidates. If such funding is not available, or not available on terms acceptable to the Company, the Company’s current development plan and plans for expansion of its general and administrative infrastructure may be curtailed. 

  

5

 

 

Note 2-Significant accounting policies

 

Basis of presentation

 

The accompanying unaudited interim condensed financial statements have been prepared in accordance with generally accepted accounting principles in the United States of America (“GAAP”) for interim financial information and the instructions to Form 10-Q and Article 8 of Regulation S-X. Accordingly, they do not include all of the information and footnotes required by GAAP for complete financial statements. In the opinion of management, the unaudited interim condensed financial statements reflect all adjustments, which include only normal recurring adjustments necessary for the fair statement of the balances and results for the periods presented. Certain information and footnote disclosures normally included in the Company’s annual financial statements prepared in accordance with GAAP have been condensed or omitted. These condensed financial statement results are not necessarily indicative of results to be expected for the full fiscal year or any future period. The accompanying unaudited condensed financial statements should be read in conjunction with the audited financial statements and notes thereto included in the Company’s Annual Report on Form 10-K filed by the Company with the SEC on April 1, 2019.

 

Use of estimates

 

The preparation of financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of expenses during the reporting periods. The most significant estimates in the Company’s financial statements relate to the valuation of preferred and common stock, stock-based compensation and the valuation allowance of deferred tax assets resulting from net operating losses. These estimates and assumptions are based on current facts, historical experience and various other factors believed to be reasonable under the circumstances, the results of which form the basis for making judgments about the carrying values of assets and liabilities and the recording of expenses that are not readily apparent from other sources. Actual results may differ materially and adversely from these estimates. To the extent there are material differences between the estimates and actual results, the Company’s future results of operations will be affected.

 

Significant Accounting Policies 

 

There have been no material changes to the Company’s significant accounting policies previously disclosed in the Company’s Annual Report on Form 10-K for the fiscal year ended December 31, 2018 as filed with the Securities and Exchange Commission (“SEC”) on April 1, 2019.

 

Restricted Cash

 

In November 2016, the Financial Accounting Standards Board (“FASB”) issued Accounting Standards Update (“ASU”) No. 2016-18, Statement of Cash Flows (Topic 230): Restricted Cash (“ASU 2016-18”), which clarifies the presentation of restricted cash in the statements of cash flows. Under ASU 2016-18, restricted cash is included with cash and cash equivalents when reconciling the beginning-of-period and end-of-period total amounts shown on the statements of cash flows. The Company adopted ASU 2016-18 during the six months ended June 30, 2019 on a retrospective basis. The following is a summary of the Company’s cash and restricted cash total as presented in the consolidated statements of cash flows for the six months ended June 30, 2019:

  

Cash  $4,092,706 
Restricted cash   200,000 
Total cash and restricted cash  $4,292,706 

 

The $0.2 million restricted cash has been deposited into a third-party escrow account in order to provide a source of funding for certain indemnification obligations the Company has pursuant to its Qualified Independent Underwriter Engagement Agreement.

 

Stock-based compensation

 

The Company expenses stock-based compensation to employees and non-employees over the requisite service period based on the estimated grant-date fair value of the awards. Stock-based awards with graded-vesting schedules are recognized on a straight-line basis over the requisite service period for each separately vesting portion of the award. The Company records the expense for stock-based compensation awards subject to performance-based milestone vesting over the remaining service period when management determines that achievement of the milestone is probable. Management evaluates when the achievement of a performance-based milestone is probable based on the expected satisfaction of the performance conditions at each reporting date. All stock-based compensation costs are recorded in general and administrative or research and development costs in the statements of operations based upon the underlying employees’ or non-employees’ roles within the Company.

  

6

 

 

Net loss per share

 

Net loss per share is computed by dividing net loss by the weighted average number of common stock outstanding during the period. Since the Company had a net loss in the periods presented, basic and diluted net loss per common share are the same. The following were excluded from the computation of diluted shares outstanding due to the losses for each period presented, as they would have had an anti-dilutive impact on the Company’s net loss:

  

   As of June 30 
Potentially dilutive securities  2019   2018 
Series A Convertible Preferred Stock (Common Stock Equivalent)   -    3,102,480 
Warrants   767,870    991,367 
Non-vested restricted stock units   17,364    - 
Total   785,234    4,093,847 

 

Recent accounting pronouncements

 

In February 2016, the FASB issued ASU No. 2016-02, Leases (Topic 842), which supersedes FASB Accounting Standards Codification (“ASC”) Topic 840, Leases (Topic 840) and provides principles for the recognition, measurement, presentation and disclosure of leases for both lessees and lessors. The new standard requires lessees to apply a dual approach, classifying leases as either finance or operating leases based on the principle of whether or not the lease is effectively a financed purchase by the lessee. This classification will determine whether lease expense is recognized based on an effective interest method or on a straight-line basis over the term of the lease. A lessee is also required to record a right-of-use asset and a lease liability for all leases with a term of greater than twelve months regardless of classification. Leases with a term of twelve months or less will be accounted for similar to existing guidance for operating leases. The standard is effective for annual and interim periods beginning after December 15, 2018, with early adoption permitted upon issuance. The Company does not have any long-term leases, therefore the adoption of this standard on January 1, 2019 did not have an impact on the Company’s condensed financial position and results of operations.

 

In June 2018, the FASB issued ASU 2018-07, Compensation—Stock Compensation (Topic 718): Improvements to Non-employee Share-Based Payment Accounting (“ASU 2018-07”). ASU 2018-07 simplifies several aspects of the accounting for non-employee share-based payment transactions resulting from expanding the scope of Topic 718, Compensation—Stock Compensation, to include share-based payment transactions for acquiring goods and services from non-employees. ASU 2018-07 is effective for public business entities for fiscal years beginning after December 15, 2018, including interim periods within that fiscal year. The Company adopted ASU 2018-07 on January 1, 2019.  Subsequent to the adoption of ASU 2018-07, the Company recognizes non-employee compensation costs over the requisite service period based on a measurement of fair value for each stock award.

 

Management does not believe that any other recently issued, but not yet effective accounting pronouncements, if currently adopted, would have an effect on the Company’s financial statements.

 

Note 3 - License agreements

 

Chelexa BioSciences, Inc.

 

On May 26, 2017, the Company entered into a sublicense agreement with  Chelexa BioSciences, Inc. (“Chelexa”) as amended on August 22, 2018 and August 29, 2018. The term of such agreement will expire on the later of April 16, 2034 and the last to expire patent in the patent rights granted to the Company (the “Term”). The Company shall, in its sole discretion, have the first right of refusal to renew the Term. The Company is subject to total milestone payments of $3.5 million and has agreed to fund all development and commercialization costs related to the licensed products. In addition, during the Term, the Company shall pay royalty payments which shall be based on a percentage of annual aggregate net sales.

 

University of Maryland and Isoprene Pharmaceuticals, Inc.

 

On March 8, 2019, the Company, the University of Maryland, Baltimore (“UMD”) and Isoprene Pharmaceuticals, Inc. (“Isoprene”) entered into a commercial evaluation sublicense and option agreement. In consideration of the rights granted under the agreement, the Company paid an initial option and material access fee of $5,000 to UMD and $5,000 to Isoprene. In the event that Isoprene enters into a master license agreement with UMD (the “MLA”), UMD shall permit Isoprene to grant an exclusive option to the Company to negotiate and obtain an exclusive sublicensable, worldwide royalty-bearing license to the subject technology (the “Isoprene-Hoth Option”); provided, however, in the event Isoprene does not enter into the MLA, UMD may grant the Company an option to negotiate and obtain an exclusive sublicensable, worldwide royalty-bearing license to the subject technology (the “UMD-Hoth Option”). If the Company exercises the Isoprene-Hoth Option, it shall pay Isoprene an option exercise fee of $20,000. If the Company exercises the UMD-Hoth Option, it shall pay UMD an option exercise fee of $20,000.

 

Zylö Therapeutics Inc.

 

On May 10, 2019, the Company and Zylö Therapeutics Inc. (“Zylö”) entered into a term sheet (the “Zylö Term Sheet”) with respect to the potential development and commercialization of certain licensed products. As of June 30, 2019, the Company paid Zylö $10,000 upon execution of the Zylö Term Sheet.

 

7

 

 

Note 4-Stockholders’ Equity 

 

Preferred Stock

 

The Company is authorized to issue up to 10,000,000 shares of preferred stock. This preferred stock may be issued in one or more series, and shall have such designations, preferences and relative, participating, optional or other special rights and qualifications, limitations or restrictions thereof as shall be determined at the time of issuance by its board of directors without further action by shareholders. As of June 30, 2019, 5,000,000 shares of the Company’s preferred stock has been designated as Series A Preferred Stock. At the time of the IPO, 3,102,480 shares of Series A Preferred Stock which were previously issued were converted into common stock and 1,897,520 shares of Series A Preferred Stock remained authorized.

 

Common Shares

 

On February 15, 2019, the Company announced the pricing of its initial public offering of 1,250,000 shares of its common stock at an initial offering price to the public of $5.60 per share. The Company issued an aggregate of 1,250,000 shares of common stock and received net proceeds of $5.8 million from the IPO.

 

Restricted Stock Awards

 

A summary of the Company’s restricted stock awards activities under the Company’s 2018 Equity Incentive Plan (the “2018 Plan”) during the six months ended June 30, 2019 is as follows:

  

   Number of Units   Weighted Average
Grant Day
Fair Value		 
Nonvested at May 16, 2017 (inception)   -   $- 
Nonvested at December 31, 2017   -    - 
Granted   37,500    0.25 
Vested   (15,970)   0.25 
Nonvested at December 31, 2018   21,530   $0.25 
Vested   (4,166)  $0.25 
Nonvested at June 30, 2019   17,364   $0.25 

 

As of June 30, 2019, the Company had approximately $8,000 of unrecognized stock-based compensation expense which was related to restricted stock awards. The weighted average remaining contractual terms of unvested restricted stock awards is approximately 1.01 years at June 30, 2019.

 

Stock Options

 

On March 6, 2019, the Company granted 50,000 options to purchase common stock of the Company to its CFO pursuant to the 2018 Plan. The aggregate grant date fair value of these options was approximately $0.2 million. The stock options vested in full upon grant.

 

Warrants

 

A summary of warrant activity for the six months ended June 30, 2019 is presented below:

  

   Number of
Warrants		   Weighted Average
Exercise Price		   Total
Intrinsic
Value		   Weighted Average Remaining Contractual Life (in years) 
Outstanding as of December 31, 2018   991,367   $1.00   $-    5.4 
Issued   66,333    5.28    94,731    4.9 
Exercised   (289,830)   0.94    -    - 
Outstanding as of June 30, 2019   767,870   $1.39   $3,452,955    5.6 
Warrants exercisable as of June 30, 2019   767,870   $1.39   $3,452,955    5.6 

 

On February 20, 2019, Laidlaw received five-year warrants to purchase 50,000 shares of the Company’s common stock at an exercise price of $7.00 per share. These warrants are not exercisable prior to August 13, 2019.

  

8

 

 

On April 17, 2019, the Company entered into a Master Service Agreement (the “MSA”) with a consultant (the “Consultant”). In consideration for services provided by the Consultant, the Company issued the Consultant a two year warrant to purchase up to 50,000 shares of the Company’s common stock at an exercise price of $0.01 per share (the “Consultant Warrant”). On May 22, 2019, the Company and Consultant agreed to terminate the MSA and number of shares of the Company’s common stock issuable upon exercise of the Consultant Warrant was reduced to 16,333. On June 27, 2019, the Company issued 16,333 shares of common stock upon exercise of the Consultant Warrant which resulted in gross proceeds of approximately $163.

 

On April 16, 2019, the Company issued 176,272 shares of common stock upon the cashless exercise of warrants to purchase up to 215,747 shares of common stock. Those warrants were issued by the Company to Laidlaw pursuant to the terms of its engagement letter with Laidlaw with respect to the private placement of its securities through October 2017 to December 2017.

 

On June 6, 2019, the Company issued 47,605 shares of common stock upon the cashless exercise of warrants to purchase up to 57,750 shares of common stock.

 

The Company has determined that the warrants should be accounted as a component of stockholders’ equity.

 

Stock Based Compensation

 

Stock-based compensation expense for the three and six months ended June 30, 2019 and 2018 was as follows:

  

   For the Three Months Ended
June 30,		   For the Six Months Ended
June 30,		 
   2019   2018   2019   2018 
Employee common stock awards  $-   $117,500   $-   $132,500 
Employee stock option awards   -    -    199,182    - 
Employee restricted stock awards   2,761    -    6,289    - 
Non-employee warrant awards   84,605         84,605      
   $87,366   $117,500   $290,075   $132,500 

 

In addition, the Company recorded $0 and $13,000 of stock issued for research and development services for the three months ended June 30, 2019 and 2018, respectively, and $0 and $24,000 of stock issued for research and development services for the six months ended June 30, 2019 and 2018, respectively.

 

Employee related stock based compensation is recognized as “compensation and related expenses” and non-employee related stock based compensation is recognized as “professional fees” in the condensed statements of operations. 

 

Note 5-Commitments and contingencies

 

Office lease

 

The Company leases office space that commenced on July 15, 2017, for approximately $2,000 a month. Rent expense for the six months ended June 30, 2019 and 2018 was approximately $15,000 and $12,000, respectively. The term of the lease expires on July 31, 2020. In accordance with ASC 842, this lease meets the definition of a short-term lease and accordingly, is not subject to capitalization.

 

Litigation

 

The Company is not a party to any material legal proceedings and is not aware of any pending or threatened claims. From time to time, the Company may be subject to various legal proceedings and claims that arise in the ordinary course of its business activities. 

  

9

 

 

ITEM 2.MANAGEMENT’S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS.

 

You should read the following discussion and analysis of our financial condition and results of operations together with and our financial statements and the related notes appearing elsewhere in this Quarterly Report on Form 10-Q. In addition to historical information, this discussion and analysis contains forward-looking statements that involve risks, uncertainties and assumptions. Our actual results may differ materially from those discussed below. Factors that could cause or contribute to such differences include, but are not limited to, those identified below, and those discussed in the section titled “Risk Factors” included in our Annual Report on Form 10-K for the fiscal year ended December 31, 2018. All amounts in this report are in U.S. dollars, unless otherwise noted.

 

Overview

 

We are a biopharmaceutical company formed in May 2017 focused on targeted therapeutics for patients suffering from conditions such as atopic dermatitis, also known as eczema.

 

Our primary asset is a sublicense agreement with Chelexa Biosciences, Inc. (“Chelexa”) pursuant to which Chelexa has granted us an exclusive sublicense to use its BioLexa Platform (as defined herein), a proprietary, patented, drug compound platform developed at the University of Cincinnati. The license enables us to develop the platform for any indications in humans. Our initial focus will be on the treatment of eczema through the application of a topical cream. Although our initial focus will be on the treatment of eczema, we intend to develop a second topical cream which, upon application, is intended to reduce post-procedure infections, accelerate healing and improve clinical outcomes for patients undergoing aesthetic dermatology procedures. The BioLexa Platform combines a U.S. Food and Drug Administration (“FDA”) approved zinc chelator with one or more approved antibiotics in a topical dosage form to address unchecked eczema flare-ups by preventing the formation of infectious biofilms and the resulting clogging of sweat ducts which trigger symptoms. It is the first product candidate intended to prevent the symptom triggering flare-ups rather than simply treating symptoms when they occur.

 

On May 26, 2017, we entered into a sublicense agreement with Chelexa, as amended on August 22, 2018 and August 29, 2018, pursuant to which Chelexa granted us an exclusive sublicense to make, use, have made, import, offer for sale, and sell products based upon or involving the use of (i) topical compositions comprising a zinc chelator and gentamicin and (ii) zinc chelators to inhibit biofilm formation (the “BioLexa Platform” or “BioLexa”), which rights were originally granted to Chelexa pursuant to an exclusive license agreement with the University of Cincinnati. In addition, Chelexa granted us the right to issue exclusive and nonexclusive sublicenses (with the right to further sublicense to third parties) to make, use, have made, import, offer for sale, and sell products based upon the BioLexa Platform.

 

We intend to initially use the BioLexa Platform to develop two different topical cream products: (i) a product to treat eczema and (ii) a product that reduces post-procedure infections, accelerates healing and improves clinical outcomes for patients undergoing aesthetic dermatology procedures. Eczema is a disease that results in inflammation of the skin and is characterized by rash, red skin, and itchiness. Eczema is also referred to as atopic dermatitis. We are concentrating our effort and resources to develop the BioLexa Platform, utilizing our novel formulation and approach for these two markets.

 

The BioLexa Platform has achieved positive results in its initial clinical studies conducted at the University of Miami. BioLexa’s formulation is a new topical dosage form “repurposing” the antibiotic, enabling it to be developed for use in patients following a special regulatory pathway codified in Section 505(b)(2) of the FDA rules. Section 505(b)(2) of the U.S. Federal Food, Drug and Cosmetic Act was enacted to enable sponsors to seek New Drug Application (“NDA”) approval for novel repurposed drugs without the need for such sponsors to undertake time consuming and expensive pre-clinical safety studies and Phase 1 safety studies. Proceeding under this regulatory pathway, we will be able to rely upon all of the publicly available safety and toxicology data with respect to gentamicin and zinc chelator in our FDA submissions. We will be required to conduct a Phase 2 study to show the safety of the combination in humans and after such Phase 2 study will be required to proceed to Phase 3 pivotal clinical trials. We believe that this path will dramatically reduce the required clinical development effort, costs and risks as compared to what would be required of us if we were required to conduct pre-clinical safety, toxicology and animal studies together with Phase 1 human safety trials required for new chemical entities which are not eligible to be reviewed pursuant to the Section 505(b)(2) regulatory pathway. We estimate that by using the Section 505(b)(2) regulatory pathway, that the clinical development process may be five to six years shorter than is required for a new chemical entity, and the FDA approval process may be six to nine months shorter than the typical eighteen month period, which we believe may result in lower development costs and shorter development time. As of the date hereof, we have not submitted an NDA to the FDA. In September 2018, we attended the first of a planned series of meetings with the FDA to review the requirements for submission and activation of an investigational new drug application (“IND”) with respect to the BioLexa Platform for use in eczema. In preparation for such pre-IND meeting, we prepared and presented to the FDA our proposed Phase 2 clinical trial plan for the treatment of eczema in patients over the age of one year old. As part of our pre-IND meeting, the FDA provided us with general guidance with respect to specific animal studies, dosing schedules and suggested human safety studies before we commence clinical trials in pediatric or adult patients. We are currently investigating multiple potential venues for conducting such trial both in and outstand of the U.S. We have engaged Camargo Pharmaceutical Services, LLC (“Camargo”) to assist us with the FDA process required for Section 505(b)(2) applications and with the evaluation of potential clinical trial venues for the proof of concept study should we determine to undertake such study. Specifically, Camargo has provided and will continue to provide advice and guidance relative to the IND preparation phase for the BioLexa Platform. Camargo will assist us with the refinement of our non-clinical, clinical, clinical pharmacology and biopharmaceutics strategy incorporating the preliminary feedback we received from the FDA during our pre-IND meeting.

  

10

 

 

We intend to conduct our first Phase 1 study in healthy adults with an immediate transition to a randomized, vehicle controlled Phase 1b trial in adolescent eczema patients comparing BioLexa to the base vehicle. This Phase 1b trial is intended to examine both safety and efficacy. We will assess the formulation of Ca-DTPA and Gentamicin 0.1% in our proprietary topical lotion delivered by a metered pump system. We will also assess the ability of BioLexa to clear harmful staph aureus bacterial from the skin of atopic dermatitis patients.

Following our Phase 1b trial, we intend to conduct up to two Phase 2 trials in atopic dermatitis patients comparing BioLexa to the base vehicle. Subject numbers and allocation will be informed by the results of the Phase 1b trial. We expect the clinical program to be completed, subject to receipt of funding by us, by the end of 2020 or early 2021 with an NDA submission targeted for mid to late 2021.

  

In addition, we conducted an initial pilot study on the efficacy of BioLexa to accelerate diabetic wound healing and intend to conduct additional studies with respect to the regenerative effects of the BioLexa Platform in the context of chronic diabetic ulcers, with and without substantial bacterial burden.

  

We believe that the key elements for our market success include:

 

  ● the proprietary formulation of two FDA-approved drugs to treat bacterial proliferation reduces development time and costs by giving us the ability to rely on safety and efficacy data from the two approved drugs;

 

  ● our proprietary formulation is not a topical corticosteroid, and may not be subject to the same FDA black box warning issues as most commonly prescribed treatments currently in use; and

 

  ● a recent peer-reviewed publication titled “Staphylococcal Bacteria May Cause Eczema, Study Reveals”, published by Dr. Herbert B. Allen, highlights that staph-induced biofilms are the root cause of flare-ups in eczema. Our BioLexa product candidate has been demonstrated to prevent the formation of these biofilms with the promise of delaying or completely arresting flare-ups, rather than merely treating symptoms of a flare-up already underway.

 

In addition to our sublicense agreement with Chelexa, we entered into an exclusive license agreement with the University of Cincinnati for a patented, novel genetic marker for food allergies. The genetic marker licensed by us from the University of Cincinnati (i) may be used to identify at risk infants in predicting food allergies, including peanut and milk allergies, (ii) may be used to identify a person’s predisposition to an allergic reaction, thereby avoiding such reaction and (iii) may also determine an individual’s propensity to develop atopic dermatitis, such as eczema. We intend to utilize the genetic marker for purposes of determining an individual’s propensity to develop eczema as well as to identify and treat allergies in at-risk infants.

 

In order to generate revenue from our product candidates, we will need to sell our product candidates either through distribution partnerships or through our own sales efforts. Prior to selling our product candidates, we will need to receive FDA approval of our NDA for each indication that we intend to treat. The first indication we are seeking approval for is the BioLexa Platform for treating eczema. We intend to submit our NDA for such indication by the end of 2021 with approval of such NDA anticipated to be in 2022; however, no assurances can be given that we will receive approval of the NDA in a timely manner, if at all.  

 

Results of Operations

 

Comparison of the Three Months Ended June 30, 2019 and 2018

 

Operating Costs and Expenses

 

Research and Development Expenses

 

For the three months ended June 30, 2019, research and development expenses were approximately $0.4 million, of which $10,000 was related to a term sheet entered into between the Company and Zylö Therapeutics Inc. (the “Zylö Term Sheet”) and approximately $0.4 million was related to other research and development expenses.

 

During the three months ended June 30, 2018, research and development expenses were approximately $0.2 million, of which approximately $32,000 was related to the acquisition of a license from University of Cincinnati and approximately $0.2 million was related to other research and development expenses.

  

11

 

 

We expect our research and development activities to increase as we develop our existing product candidate and potentially acquire new product candidates, reflecting increasing costs associated with the following:

 

  ● employee-related expenses, which include salaries and benefits, and rent expenses;

 

  ● license fees and milestone payments related to in-licensed products and technology;

 

  ● expenses incurred under agreements with contract research organizations, investigative sites and consultants that conduct our clinical trials and a substantial portion of our preclinical activities;

 

  ● the cost of acquiring and manufacturing clinical trial materials; and

 

  ● costs associated with non-clinical activities, and regulatory approvals.

 

Compensation, Professional Fees, Rent and Other (“General and Administrative Expenses”)

 

For the three months ended June 30, 2019, general and administrative expenses were approximately $0.9 million, which primarily consisted of approximately $0.1 million related to payroll expenses and stock-based compensation, $0.5 million for professional fees and $0.2 million for other expenses.

 

During the three months ended June 30, 2018, general and administrative expenses were approximately $0.5 million, which primarily consisted of approximately $0.2 million related to payroll expenses and approximately $0.2 million for professional fees.

 

We anticipate that our general and administrative expenses will increase in future periods, reflecting continued and increasing costs associated with:

 

  ● support of our research and development activities;

 

  ● stock compensation granted to key employees and non-employees;

 

  ● support of business development activities; and

 

  ● increased professional fees and other costs associated with the regulatory requirements and increased compliance associated with being a public reporting company.

 

Comparison of the Six Months Ended June 30, 2019 and 2018

 

Operating Costs and Expenses

 

Research and Development Expenses

 

For the six months ended June 30, 2019, research and development expenses were approximately $0.5 million, of which $10,000 was related to the Zylö Term Sheet, an aggregate of $10,000 was related to a license acquired from the University of Maryland and Isoprene Pharmaceuticals Inc., and approximately $0.4 million was related to other research and development expenses.

 

During the six months ended June 30, 2018, research and development expenses were approximately $0.4 million, of which $32,000 was related to the acquisition of a license from University of Cincinnati and $0.1 million was related to the acquisition of a license from Chelexa Biosciences, Inc. Pursuant to the terms of the sublicense agreement, we issued Chelexa 0.2 million shares of our common stock valued at $0.1 million. In addition, we incurred approximately $0.3 million of expense related to other research and development expenses.

 

Compensation, Professional Fees, Rent and Other

 

For the six months ended June 30, 2019, general and administrative expenses were approximately $1.6 million, which primarily consisted of approximately $0.5 million related to payroll expenses and stock-based compensation and approximately $0.8 million for professional fees.

 

During the six months ended June 30, 2018, general and administrative expenses were $0.9 million, which primarily consisted of $0.3 million related to payroll expenses and $0.4 million for professional fees.

  

12

 

 

Liquidity and Capital Resources

 

We have incurred substantial operating losses since inception, and expect to continue to incur significant operating losses for the foreseeable future and may never become profitable. As of June 30, 2019, we had approximately $4.1 million in cash and an accumulated deficit of approximately $6.6 million.

 

We have funded our operations from proceeds from the sale of equity and debt securities. We will require significant additional capital to make the investments we need to execute our longer-term business plan. Our ability to successfully raise sufficient funds through the sale of debt or equity securities when needed is subject to many risks and uncertainties and, even if we are successful, future equity issuances would result in dilution to its existing stockholders and any future debt securities may contain covenants that limit our operations or ability to enter into certain transactions.

 

The proceeds from our initial public offering (the “IPO”) and the current cash are sufficient to fund operations for at least the next 12 months; however, we will need to raise significant additional capital to continue to fund our operations and the clinical trials for BioLexa. We may seek to sell common stock, preferred stock or convertible debt securities, enter into a credit facility or another form of third-party funding or seek other debt financing. In addition, we may seek to raise cash through collaborative agreements or from government grants. The sale of equity and convertible debt securities may result in dilution to our stockholders and certain of those securities may have rights senior to those of our common shares. If we raise additional funds through the issuance of preferred stock, convertible debt securities or other debt financing, these securities or other debt could contain covenants that would restrict our operations. Any other third-party funding arrangement could require us to relinquish valuable rights.

 

The source, timing and availability of any future financing will depend principally upon market conditions, and, more specifically, on the progress of our clinical development program. Funding may not be available when needed, at all, or on terms acceptable to us. Lack of necessary funds may require us to, among other things, delay, scale back or eliminate expenses including some or all of our planned development, including our clinical trials.

 

Cash Flows from Operating Activities

 

For the six months ended June 30, 2019, net cash used in operations was $1.8 million, which primarily resulted from a net loss of $2.1 million.

 

For the six months ended June 30, 2018, net cash used in operations was $0.9 million, which primarily resulted from a net loss of $1.3 million, partially offset by $0.1 million of non-cash research and development expense related to a license acquisition.

 

Cash Flows from Investing Activities

 

For the six months ended June 30, 2019, net cash used in investing activities was $20,000, which was related to the purchase of research and development licenses.

 

For the six months ended June 30, 2018, there were no investing activities.

 


Cash Flows from Financing Activities

 

For the six months ended June 30, 2019, net cash provided by financing activities was $5.8 million, including $0.2 million restricted cash, from the net proceeds of the IPO. The $0.2 million restricted cash has been deposited into a third-party escrow account in order to provide a source of funding for certain indemnification obligations the Company has pursuant to its Qualified Independent Underwriter Engagement Agreement.

 

On February 20, 2019, we closed the IPO pursuant to which we issued 1,250,000 shares of our common stock for net proceeds of approximately $5.8 million, after deducting underwriting discounts and commissions and offering expenses.

 

For the six months ended June 30, 2018, net cash provided by financing activities was $1.2 million, which reflects the net proceeds from investors in consideration for the issuance of 13.77 units of our securities.

 

Off-Balance Sheet Arrangements; Commitments and Contractual Obligations

 

As of June 30, 2019, we did not have any off-balance sheet arrangements as defined in Item 303(a)(4)(ii) of Regulation S-K and did not have any commitments or contractual obligations.

  

13

 

 

JOBS Act

 

On April 5, 2012, the Jumpstart Our Business Startups Act of 2012 (the “JOBS Act”) was enacted. Section 107 of the JOBS Act provides that an “emerging growth company” can take advantage of the extended transition period provided in Section 7(a)(2)(B) of the Securities Act for complying with new or revised accounting standards. In other words, an “emerging growth company” can delay the adoption of certain accounting standards until those standards would otherwise apply to private companies.

 

We have chosen to take advantage of the extended transition periods available to emerging growth companies under the JOBS Act for complying with new or revised accounting standards until those standards would otherwise apply to private companies provided under the JOBS Act. As a result, our financial statements may not be comparable to those of companies that comply with public company effective dates for complying with new or revised accounting standards.

 

We are in the process of evaluating the benefits of relying on other exemptions and reduced reporting requirements provided by the JOBS Act. Subject to certain conditions set forth in the JOBS Act, as an “emerging growth company,” we intend to rely on certain of these exemptions, including, without limitation, (i) providing an auditor’s attestation report on our system of internal controls over financial reporting pursuant to Section 404(b) of the Sarbanes-Oxley Act and (ii) complying with any requirement that may be adopted by the Public Company Accounting Oversight Board regarding mandatory audit firm rotation or a supplement to the auditor’s report providing additional information about the audit and the financial statements, known as the auditor discussion and analysis. We will remain an “emerging growth company” until the earliest of (i) the last day of the fiscal year in which we have total annual gross revenues of $1.07 billion or more; (ii) the last day of our fiscal year following the fifth anniversary of the date of the IPO; (iii) the date on which we have issued more than $1 billion in nonconvertible debt during the previous three years; or (iv) the date on which we are deemed to be a large accelerated filer under the rules of the SEC.

 

ITEM 3.QUANTITATIVE AND QUALITATIVE DISCLOSURES ABOUT MARKET RISK.

 

The Company is not required to provide the information required by this Item as it is a “smaller reporting company,” as defined in Rule 229.10(f)(1).

 

ITEM 4.CONTROLS AND PROCEDURES.

 

Evaluation of Disclosure Controls and Procedures

 

We maintain “disclosure controls and procedures,” as defined in Rule 13a-15(e) and Rule 15d-15(e) under the Securities Exchange Act of 1934 (the “Exchange Act”) that are designed to ensure that information required to be disclosed by a company in the reports that it files or submits under the Exchange Act is recorded, processed, summarized and reported, within the time periods specified in the SEC’s rules and forms. Disclosure controls and procedures include, without limitation, controls and procedures designed to ensure that information required to be disclosed by a company in the reports that it files or submits under the Exchange Act is accumulated and communicated to our management, including our principal executive and principal financial officers, as appropriate to allow timely decisions regarding required disclosure.

 

Our management, with the participation of our Chief Executive Officer and Chief Financial Officer, has evaluated the effectiveness of our disclosure controls and procedures (as defined in Rules 13a-15(e) and 15d-15(e) under the Exchange Act), as of the end of the period covered by this Quarterly Report on Form 10-Q. Based on such evaluation, our Chief Executive Officer and Chief Financial Officer have concluded that as of June 30, 2019, our disclosure controls and procedures were effective.

 

Changes in Internal Control

 

There were no changes in our internal control over financial reporting identified in management’s evaluation pursuant to Rules 13a-15(d) or 15d-15(d) of the Exchange Act during the period covered by this Quarterly Report on Form 10-Q that materially affected, or are reasonably likely to materially affect, our internal control over financial reporting.

 

Limitations on Effectiveness of Controls and Procedures

 

In designing and evaluating the disclosure controls and procedures, management recognizes that any controls and procedures, no matter how well designed and operated, can provide only reasonable assurance of achieving the desired control objectives. In addition, the design of disclosure controls and procedures must reflect the fact that there are resource constraints and that management is required to apply judgment in evaluating the benefits of possible controls and procedures relative to their costs.

  

14

 

 

 PART II — OTHER INFORMATION

 

ITEM 1.LEGAL PROCEEDINGS.

 

From time to time, we may be subject to litigation and claims arising in the ordinary course of business. We are not currently a party to any material legal proceedings and we are not aware of any pending or threatened legal proceeding against us that we believe could have a material adverse effect on our business, operating results, cash flows or financial condition.

 

ITEM 1A.RISK FACTORS.

 

The Company is not required to provide the information required by this Item as it is a “smaller reporting company,” as defined in Rule 229.10(f)(1).

 

ITEM 2.UNREGISTERED SALES OF EQUITY SECURITIES AND USE OF PROCEEDS.

 

On April 16, 2019, the Company issued an aggregate of 176,272 shares of common stock upon the cashless exercise of warrants to purchase up to an aggregate of 215,747 shares of common stock.

On April 17, 2019, the Company entered into a Master Service Agreement (the “MSA”) with a consultant (the “Consultant”). In consideration for services provided by the Consultant, the Company issued the Consultant a two year warrant to purchase up to 50,000 shares of the Company’s common stock at an exercise price of $0.01 per share (the “Consultant Warrant”). On May 22, 2019, the Company and Consultant agreed to terminate the MSA and number of shares of the Company’s common stock issuable upon exercise of the Consultant Warrant was reduced to 16,333. On June 27, 2019, the Company issued 16,333 shares of common stock upon exercise of the Consultant Warrant.

On June 6, 2019, the Company issued an aggregate of 47,605 shares of common stock upon the cashless exercise of warrants to purchase up to an aggregate of 57,750 shares of common stock.

From April 1, 2019 until June 30, 2019, the Company issued an aggregate of 2,082 shares of the Company’s common stock granted in 2018 to a member of the Company’s Board for services rendered as a result of such shares vesting during such time period. 

The foregoing issuances were exempt from registration under Section 4(a)(2) of the Securities Act. 

ITEM 3.DEFAULTS UPON SENIOR SECURITIES.

 

None.

 

ITEM 4.MINE SAFETY DISCLOSURES.

 

Not applicable.

 

ITEM 5.OTHER INFORMATION.

 

None.

  

15

 

 

ITEM 6.EXHIBITS.

 

Exhibit No.   Description
3.1   Articles of Incorporation (Incorporated by reference to Exhibit 3.1 to the Company’s Form S-1 filed on December 14, 2018)
     
3.2   Amendment to Articles of Incorporation (Incorporated by reference to Exhibit 3.2 to the Company’s Form S-1 filed on December 14, 2018)
     
3.3   Certificate of Designations, Preferences and Rights of the Series A Convertible Preferred Stock (Incorporated by reference to Exhibit 3.3 to the Company’s Form S-1 filed on December 14, 2018)
     
3.4   Amendment to Articles of Incorporation (Incorporated by reference to Exhibit 3.1 to the Company’s Form 8-K filed on February 20, 2019)
     
3.5   Amended and Restated Bylaws (Incorporated by reference to Exhibit 3.2 to the Company’s Form 8-K filed on February 20, 2019)
     
31.1*   Certification of Principal Executive Officer Pursuant to Rules 13a-14(a) and 15d-14(a) under the Securities Exchange Act of 1934, as Adopted Pursuant to Section 302 of the Sarbanes-Oxley Act of 2002
     
31.2*   Certification of Principal Financial Officer Pursuant to Rules 13a-14(a) and 15d-14(a) under the Securities Exchange Act of 1934, as Adopted Pursuant to Section 302 of the Sarbanes-Oxley Act of 2002
     
32.1*   Certification of Principal Executive Officer Pursuant to 18 U.S.C. Section 1350, as Adopted Pursuant to Section 906 of the Sarbanes-Oxley Act of 2002
     
32.2*   Certification of Principal Financial Officer Pursuant to 18 U.S.C. Section 1350, as Adopted Pursuant to Section 906 of the Sarbanes-Oxley Act of 2002
     
101.INS*   XBRL Instance Document
     
101.SCH*   XBRL Taxonomy Extension Schema Document
     
101.CAL*   XBRL Taxonomy Extension Calculation Linkbase Document
     
101.DEF*   XBRL Taxonomy Extension Definition Linkbase Document
     
101.LAB*   XBRL Taxonomy Extension Label Linkbase Document
     
101.PRE*   XBRL Taxonomy Extension Presentation Linkbase Document

 

*Filed herewith.

  

16

 

 

SIGNATURES

 

Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.

 

  HOTH THERAPEUTICS, INC.
     
Date:  August 14, 2019 By: /s/ Robb Knie
    Robb Knie,
Chief Executive Officer
(Principal Executive Officer)
     
Date:  August 14, 2019 By: /s/ David Briones
    David Briones,
Chief Financial Officer
(Principal Financial and Accounting Officer)

 

 

17

 

 EX-31.1 2 f10q0619ex31-1_hoth.htm CERTIFICATION

Exhibit 31.1

 

Certification of Chief Executive Officer of Hoth Therapeutics, Inc.
Pursuant to Section 302 of the Sarbanes-Oxley Act of 2002

 

I, Robb Knie, certify that:

 

1.I have reviewed this quarterly report on Form 10-Q of Hoth Therapeutics, Inc.;

 

2.Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;

 

3.Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;

 

4.The registrant’s other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15(d)-15(f)) for the registrant and have:

 

  a. Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;

 

  b. Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;

 

  c. Evaluated the effectiveness of the registrant’s disclosure controls and procedures, and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and

 

  d. Disclosed in this report any change in the registrant’s internal control over financial reporting that occurred during the registrant’s most recent fiscal quarter (the registrant’s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant’s internal control over financial reporting; and

 

5.The registrant’s other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant’s auditors and the audit committee of the registrant’s board of directors (or persons performing the equivalent functions):

 

  a. All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant’s ability to record, process, summarize and report financial information; and

 

  b. Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant’s internal control over financial reporting.

 

Date: August 14, 2019 /s/ Robb Knie
  Robb Knie,
Chief Executive Officer
(Principal Executive Officer)

 EX-31.2 3 f10q0619ex31-2_hoth.htm CERTIFICATION

Exhibit 31.2

 

Certification of Chief Financial Officer of Hoth Therapeutics, Inc.
Pursuant to Section 302 of the Sarbanes-Oxley Act of 2002

 

I, David Briones, certify that:

 

1.I have reviewed this quarterly report on Form 10-Q of Hoth Therapeutics, Inc.;

 

2.Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;

 

3.Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;

 

4.The registrant’s other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15(d)-15(f)) for the registrant and have:

 

  a. Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;

 

  b. Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;

 

  c. Evaluated the effectiveness of the registrant’s disclosure controls and procedures, and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and

 

  d. Disclosed in this report any change in the registrant’s internal control over financial reporting that occurred during the registrant’s most recent fiscal quarter (the registrant’s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant’s internal control over financial reporting; and

 

5.The registrant’s other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant’s auditors and the audit committee of the registrant’s board of directors (or persons performing the equivalent functions):

 

  a. All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant’s ability to record, process, summarize and report financial information; and

 

  b. Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant’s internal control over financial reporting.

 

Date: August 14, 2019 /s/ David Briones
  David Briones,
Chief Financial Officer
(Principal Financial and Accounting Officer)

  

 EX-32.1 4 f10q0619ex32-1_hoth.htm CERTIFICATION

Exhibit 32.1

 

Statement of Chief Executive Officer
Pursuant to Section 1350 of Title 18 of the United States Code

 

Pursuant to Section 1350 of Title 18 of the United States Code as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, the undersigned, Robb Knie, Chief Executive Officer of Hoth Therapeutics, Inc. (the “Company”), hereby certifies that based on the undersigned’s knowledge:

 

1.The Company’s quarterly report on Form 10-Q for the period ended June 30, 2019 (the “Report”) fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934; and

 

2.The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.

 

Date: August 14, 2019 /s/ Robb Knie
  Robb Knie,
 

Chief Executive Officer
(Principal Executive Officer)

  

 EX-32.2 5 f10q0619ex32-2_hoth.htm CERTIFICATION

Exhibit 32.2

 

Statement of Chief Financial Officer
Pursuant to Section 1350 of Title 18 of the United States Code

 

Pursuant to Section 1350 of Title 18 of the United States Code as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, the undersigned, David Briones, Chief Financial Officer of Hoth Therapeutics, Inc. (the “Company”), hereby certifies that based on the undersigned’s knowledge:

 

1.The Company’s quarterly report on Form 10-Q for the period ended June 30, 2019 (the “Report”) fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934; and

 

2.The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.

 

Date: August 14, 2019 /s/ David Briones
  David Briones,
Chief Financial Officer
  (Principal Financial and Accounting Officer)

  

 EX-101.INS 6 hoth-20190630.xml XBRL INSTANCE FILE 0001711786 2019-01-01 2019-06-30 0001711786 2019-06-30 0001711786 2018-12-31 0001711786 us-gaap:CommonStockMember 2019-01-01 2019-06-30 0001711786 us-gaap:CommonStockMember 2018-12-31 0001711786 us-gaap:CommonStockMember 2019-06-30 0001711786 us-gaap:AdditionalPaidInCapitalMember 2019-01-01 2019-06-30 0001711786 us-gaap:AdditionalPaidInCapitalMember 2018-12-31 0001711786 us-gaap:AdditionalPaidInCapitalMember 2019-06-30 0001711786 us-gaap:RetainedEarningsMember 2019-01-01 2019-06-30 0001711786 us-gaap:RetainedEarningsMember 2018-12-31 0001711786 us-gaap:RetainedEarningsMember 2019-06-30 0001711786 us-gaap:ConvertibleDebtSecuritiesMember 2018-01-01 2018-06-30 0001711786 us-gaap:WarrantMember 2018-01-01 2018-06-30 0001711786 hoth:NonvestedRestrictedStockUnitsMember 2018-01-01 2018-06-30 0001711786 us-gaap:ConvertibleDebtSecuritiesMember 2019-01-01 2019-06-30 0001711786 us-gaap:WarrantMember 2019-01-01 2019-06-30 0001711786 hoth:NonvestedRestrictedStockUnitsMember 2019-01-01 2019-06-30 0001711786 hoth:ChelexaBioSciencesIncMember 2019-01-01 2019-06-30 0001711786 us-gaap:PreferredStockMember 2019-06-30 0001711786 us-gaap:WarrantMember 2019-01-01 2019-06-30 0001711786 us-gaap:WarrantMember 2019-06-30 0001711786 us-gaap:WarrantMember 2018-12-31 0001711786 us-gaap:RestrictedStockUnitsRSUMember 2018-01-01 2018-06-30 0001711786 us-gaap:RestrictedStockUnitsRSUMember 2019-01-01 2019-06-30 0001711786 us-gaap:RestrictedStockUnitsRSUMember 2018-12-31 0001711786 us-gaap:RestrictedStockUnitsRSUMember 2019-06-30 0001711786 us-gaap:RestrictedStockUnitsRSUMember hoth:EmployeeCommonStockAwardsMember 2018-01-01 2018-06-30 0001711786 us-gaap:RestrictedStockUnitsRSUMember hoth:EmployeeCommonStockAwardsMember 2019-01-01 2019-06-30 0001711786 us-gaap:RestrictedStockUnitsRSUMember hoth:EmployeeRestrictedStockAwardsMember 2019-01-01 2019-06-30 0001711786 us-gaap:RestrictedStockUnitsRSUMember hoth:EmployeeRestrictedStockAwardsMember 2018-01-01 2018-06-30 0001711786 us-gaap:IPOMember 2019-02-01 2019-02-14 0001711786 us-gaap:IPOMember 2019-02-01 2019-02-15 0001711786 us-gaap:IPOMember 2019-02-15 0001711786 2018-06-30 0001711786 us-gaap:SeriesAPreferredStockMember 2019-06-30 0001711786 us-gaap:SeriesAPreferredStockMember 2018-12-31 0001711786 us-gaap:CommonStockMember 2017-12-31 0001711786 us-gaap:CommonStockMember 2018-03-31 0001711786 us-gaap:AdditionalPaidInCapitalMember 2017-12-31 0001711786 us-gaap:AdditionalPaidInCapitalMember 2018-03-31 0001711786 us-gaap:RetainedEarningsMember 2017-12-31 0001711786 us-gaap:RetainedEarningsMember 2018-03-31 0001711786 2018-03-31 0001711786 2017-12-31 0001711786 2019-03-01 2019-03-08 0001711786 us-gaap:RestrictedStockUnitsRSUMember hoth:EmployeeStockOptionAwardsMember 2019-01-01 2019-06-30 0001711786 us-gaap:RestrictedStockUnitsRSUMember hoth:EmployeeStockOptionAwardsMember 2018-01-01 2018-06-30 0001711786 us-gaap:IPOMember 2019-02-10 2019-02-15 0001711786 us-gaap:StockCompensationPlanMember 2019-03-02 2019-03-06 0001711786 2019-02-12 2019-02-20 0001711786 2019-02-20 0001711786 2018-01-01 2018-06-30 0001711786 hoth:ZyloTherapeuticsIncMember 2019-01-01 2019-06-30 0001711786 us-gaap:RestrictedStockUnitsRSUMember 2017-05-16 2017-12-31 0001711786 us-gaap:RestrictedStockUnitsRSUMember 2017-12-31 0001711786 us-gaap:RestrictedStockUnitsRSUMember 2018-01-01 2018-12-31 0001711786 us-gaap:RestrictedStockUnitsRSUMember hoth:NonEmployeeWarrantAwardsMember 2019-01-01 2019-06-30 0001711786 us-gaap:RestrictedStockUnitsRSUMember hoth:NonEmployeeWarrantAwardsMember 2018-01-01 2018-06-30 0001711786 us-gaap:RestrictedStockUnitsRSUMember hoth:EmployeeCommonStockAwardsMember 2019-04-01 2019-06-30 0001711786 us-gaap:RestrictedStockUnitsRSUMember hoth:EmployeeCommonStockAwardsMember 2018-04-01 2018-06-30 0001711786 us-gaap:RestrictedStockUnitsRSUMember hoth:EmployeeStockOptionAwardsMember 2019-04-01 2019-06-30 0001711786 us-gaap:RestrictedStockUnitsRSUMember hoth:EmployeeStockOptionAwardsMember 2018-04-01 2018-06-30 0001711786 us-gaap:RestrictedStockUnitsRSUMember hoth:EmployeeRestrictedStockAwardsMember 2019-04-01 2019-06-30 0001711786 us-gaap:RestrictedStockUnitsRSUMember hoth:EmployeeRestrictedStockAwardsMember 2018-04-01 2018-06-30 0001711786 us-gaap:RestrictedStockUnitsRSUMember hoth:NonEmployeeWarrantAwardsMember 2019-04-01 2019-06-30 0001711786 us-gaap:RestrictedStockUnitsRSUMember hoth:NonEmployeeWarrantAwardsMember 2018-04-01 2018-06-30 0001711786 us-gaap:RestrictedStockUnitsRSUMember 2019-04-01 2019-06-30 0001711786 us-gaap:RestrictedStockUnitsRSUMember 2018-04-01 2018-06-30 0001711786 2019-04-04 2019-04-17 0001711786 2019-04-17 0001711786 2019-05-06 2019-05-22 0001711786 2019-06-10 2019-06-27 0001711786 2019-04-05 2019-04-16 0001711786 2019-06-02 2019-06-06 0001711786 2018-04-01 2018-06-30 0001711786 2019-04-01 2019-06-30 0001711786 us-gaap:ConvertiblePreferredStockMember 2019-04-01 2019-06-30 0001711786 us-gaap:CommonStockMember 2019-04-01 2019-06-30 0001711786 us-gaap:CommonStockMember 2019-03-31 0001711786 us-gaap:CommonStockMember 2018-01-01 2018-06-30 0001711786 us-gaap:CommonStockMember 2018-06-30 0001711786 us-gaap:AdditionalPaidInCapitalMember 2019-04-01 2019-06-30 0001711786 us-gaap:AdditionalPaidInCapitalMember 2019-03-31 0001711786 us-gaap:AdditionalPaidInCapitalMember 2018-01-01 2018-06-30 0001711786 us-gaap:AdditionalPaidInCapitalMember 2018-06-30 0001711786 us-gaap:RetainedEarningsMember 2019-04-01 2019-06-30 0001711786 us-gaap:RetainedEarningsMember 2019-03-31 0001711786 us-gaap:RetainedEarningsMember 2018-01-01 2018-06-30 0001711786 us-gaap:RetainedEarningsMember 2018-06-30 0001711786 us-gaap:CommonStockMember 2018-04-01 2018-06-30 0001711786 us-gaap:AdditionalPaidInCapitalMember 2018-04-01 2018-06-30 0001711786 us-gaap:RetainedEarningsMember 2018-04-01 2018-06-30 0001711786 2019-03-31 0001711786 us-gaap:ConvertiblePreferredStockMember 2018-04-01 2018-06-30 0001711786 us-gaap:ConvertiblePreferredStockMember 2018-01-01 2018-06-30 0001711786 us-gaap:ConvertiblePreferredStockMember 2019-01-01 2019-06-30 0001711786 us-gaap:ConvertiblePreferredStockMember 2019-06-30 0001711786 us-gaap:ConvertiblePreferredStockMember 2018-06-30 0001711786 us-gaap:ConvertiblePreferredStockMember 2019-03-31 0001711786 us-gaap:ConvertiblePreferredStockMember 2018-03-31 0001711786 us-gaap:ConvertiblePreferredStockMember 2017-12-31 0001711786 us-gaap:ConvertiblePreferredStockMember 2018-12-31 0001711786 hoth:IsopreneHothOptionMember 2019-01-01 2019-06-30 0001711786 hoth:UMDHothOptionMember 2019-01-01 2019-06-30 0001711786 2019-08-13 iso4217:USD xbrli:shares iso4217:USD xbrli:shares Hoth Therapeutics, Inc. 0001711786 10-Q 2019-06-30 false --12-31 true false Q2 2019 Non-accelerated Filer true 4188420 154965 507 967 4665154 10795410 -4511006 -6607957 1367985 470 496 3199304 4543626 -2015481 -2543027 2001405 1184466 943 508 10707905 4673614 -5340371 -3306447 5368477 310 310 173 310 0.0001 0.0001 0.0001 0.0001 5000000 5000000 10000000 5000000 5000000 0 0 0 3102480 0 0 0 3102480 0.0001 0.0001 75000000 75000000 -2096951 -2096951 -1290966 -763420 -1267586 -1267586 -1290966 -763420 290075 290075 132500 117500 87366 14 87366 132486 11 117489 4166 2082 142500 117500 290075 132500 290075 132500 6289 199182 132500 84605 117500 2761 84605 87366 117500 4000000 785234 3102480 991367 767870 17364 4093847 3500000 767870 991367 1250000 66333 50000 1.39 1.00 5.28 3452955 94731 P4Y10M25D P5Y7M6D P5Y4M24D 1.39 3452955 P5Y7M6D 0.25 0.25 4166 15970 0.25 0.25 15000 12000 21530 17364 310 9668256 5071400 9668256 5071400 -0.25 -0.26 -0.15 -0.13 8312327 4986306 5039800 9603134 -2096951 -1290966 -763420 -1267586 2096951 1290966 763420 1267586 244705 114787 68073 182083 15263 12439 6300 8234 838364 422159 229899 544849 454935 319482 210453 133486 20000 164192 32028 10000 523684 257907 216667 388934 5071400 9668256 4706277 4956943 9425964 5086943 3102480 3102480 1725980 3102480 3102480 -3102480 310 -310 5840168 126 5840042 1250000 23500 12500 3 23497 1 12499 25000 12500 132164 21 132143 213166 164767 164767 27127 132164 310 4010085 236384 5840331 1186321 5840168 1186321 -20000 20000 -1810246 -949937 64986 80984 88964 27184 20000 132164 608 607 4100000 1250000 5.60 5800000 767870 50000 50000 7.00 0.01 2020-07-31 5000000 3102480 1897520 1250000 8000 P1Y0M4D 5800000 163 200000 5.60 23500 13000 0 4092706 200000 The Company entered into an underwriting agreement with Laidlaw & Co. (UK) Ltd. ("Laidlaw") pursuant to which the Company paid Laidlaw a fee in the amount of 7% of the gross proceeds of the IPO, or $490,000. The Company also reimbursed Laidlaw for certain out-of-pocket expenses, including the fees and disbursements of their counsel, up to an aggregate of $0.2 million. In addition, Laidlaw received five-year warrants to purchase 50,000 shares of common stock of the Company at an exercise price of $7.00 per share. 187500 <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 11pt; text-align: justify; text-indent: -11pt"><font style="font: 10pt Times New Roman, Times, Serif"><b><i>Basis of presentation</i></b></font></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 11pt; text-align: justify; text-indent: -11pt"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><font style="font: 10pt Times New Roman, Times, Serif">The accompanying unaudited interim condensed financial statements have been prepared in accordance with generally accepted accounting principles in the United States of America ("GAAP") for interim financial information and the instructions to Form 10-Q and Article 8 of Regulation S-X. Accordingly, they do not include all of the information and footnotes required by GAAP for complete financial statements. In the opinion of management, the unaudited interim condensed financial statements reflect all adjustments, which include only normal recurring adjustments necessary for the fair statement of the balances and results for the periods presented. Certain information and footnote disclosures normally included in the Company's annual financial statements prepared in accordance with GAAP have been condensed or omitted. These condensed financial statement results are not necessarily indicative of results to be expected for the full fiscal year or any future period.&#160;The accompanying unaudited condensed financial statements should be read in conjunction with the audited financial statements and notes thereto included in the Company's Annual Report on Form 10-K filed by the Company with the SEC on April 1, 2019.</font></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 11pt; text-align: justify; text-indent: -11pt"><font style="font: 10pt Times New Roman, Times, Serif"><b><i>Use of estimates</i></b></font></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><font style="font: 10pt Times New Roman, Times, Serif">The preparation of financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of expenses during the reporting periods. The most significant estimates in the Company's financial statements relate to the valuation of preferred and common stock, stock-based compensation and the valuation allowance of deferred tax assets resulting from net operating losses. These estimates and assumptions are based on current facts, historical experience and various other factors believed to be reasonable under the circumstances, the results of which form the basis for making judgments about the carrying values of assets and liabilities and the recording of expenses that are not readily apparent from other sources. Actual results may differ materially and adversely from these estimates. To the extent there are material differences between the estimates and actual results, the Company's future results of operations will be affected.</font></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><font style="font: 10pt Times New Roman, Times, Serif"><b><i>Significant Accounting Policies&#160;</i></b></font></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 44pt"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><font style="font: 10pt Times New Roman, Times, Serif">There have been no material changes to the Company's significant accounting policies previously disclosed in the Company's Annual Report on Form 10-K for the fiscal year ended December 31, 2018 as filed with the Securities and Exchange Commission ("SEC") on April 1, 2019.</font></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><font style="font: 10pt Times New Roman, Times, Serif"><b><i>Restricted Cash</i></b></font></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><font style="font: 10pt Times New Roman, Times, Serif">In November 2016, the Financial Accounting Standards Board (&#8220;FASB&#8221;) issued <i>Accounting Standards Update </i>(&#8220;ASU<i>&#8221;) No.&#160;2016-18,&#160;Statement of Cash Flows (Topic 230): Restricted Cash&#160;</i>(&#8220;ASU&#160;2016-18&#8221;)<i>,</i>&#160;which clarifies the presentation of restricted cash in the statements of cash flows. Under ASU&#160;2016-18,&#160;restricted cash is included with cash and cash equivalents when reconciling the beginning-of-period and end-of-period total amounts shown on the statements of cash flows. The Company adopted ASU&#160;2016-18&#160;during the six months ended June 30, 2019 on a retrospective basis. The following is a summary of the Company&#8217;s cash and restricted cash total as presented in the consolidated statements of cash flows for the six months ended June 30, 2019:</font></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><font style="font: 10pt Times New Roman, Times, Serif">&#160;&#160;</font></p> <table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif"> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 88%">Cash</td><td style="width: 1%">&#160;</td> <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">4,092,706</td><td style="width: 1%; text-align: left">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left; padding-bottom: 1.5pt">Restricted cash</td><td style="padding-bottom: 1.5pt">&#160;</td> <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">200,000</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; padding-bottom: 4pt">Total cash and restricted cash</td><td style="font-weight: bold; padding-bottom: 4pt">&#160;</td> <td style="border-bottom: Black 4pt double; font-weight: bold; text-align: left">$</td><td style="border-bottom: Black 4pt double; font-weight: bold; text-align: right">4,292,706</td><td style="padding-bottom: 4pt; font-weight: bold; text-align: left">&#160;</td></tr> </table> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><font style="font: 10pt Times New Roman, Times, Serif"><b><i>&#160;</i></b></font></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><font style="font: 10pt Times New Roman, Times, Serif"><b><i></i></b></font></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The $0.2 million restricted cash has been deposited into a third-party escrow account in order to provide a source of funding for certain indemnification obligations the Company has pursuant to its Qualified Independent Underwriter Engagement Agreement.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><font style="font: 10pt Times New Roman, Times, Serif"><b><i>Stock-based compensation</i></b></font></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><font style="font: 10pt Times New Roman, Times, Serif">The Company expenses stock-based compensation to employees and non-employees over the requisite service period based on the estimated grant-date fair value of the awards. Stock-based awards with graded-vesting schedules are recognized on a straight-line basis over the requisite service period for each separately vesting portion of the award. The Company records the expense for stock-based compensation awards subject to performance-based milestone vesting over the remaining service period when management determines that achievement of the milestone is probable. Management evaluates when the achievement of a performance-based milestone is probable based on the expected satisfaction of the performance conditions at each reporting date. All stock-based compensation costs are recorded in general and administrative or research and development costs in the statements of operations based upon the underlying employees' or non-employees' roles within the Company.</font></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><font style="font: 10pt Times New Roman, Times, Serif"><b><i>Net loss per share</i></b></font></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><font style="font: 10pt Times New Roman, Times, Serif"><b><i>&#160;</i></b></font></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><font style="font: 10pt Times New Roman, Times, Serif">Net loss per share is computed by dividing net loss by the weighted average number of common stock outstanding during the period. Since the Company had a net loss in the periods presented, basic and diluted net loss per common share are the same. The following were excluded from the computation of diluted shares outstanding due to the losses for each period presented, as they would have had an anti-dilutive impact on the Company's net loss:</font></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><font style="font: 10pt Times New Roman, Times, Serif">&#160;&#160;</font></p> <table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif"> <tr style="vertical-align: bottom"> <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td> <td colspan="6" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">As of June 30</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr> <tr style="vertical-align: bottom"> <td style="font-weight: bold; text-align: left; border-bottom: Black 1.5pt solid">Potentially dilutive securities</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td> <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2019</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td> <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2018</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 76%; text-align: left">Series A Convertible Preferred Stock (Common Stock Equivalent)</td><td style="width: 1%">&#160;</td> <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">-</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td> <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">3,102,480</td><td style="width: 1%; text-align: left">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left">Warrants</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">767,870</td><td style="text-align: left">&#160;</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">991,367</td><td style="text-align: left">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; padding-bottom: 1.5pt">Non-vested restricted stock units</td><td style="padding-bottom: 1.5pt">&#160;</td> <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">17,364</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td> <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">-</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left; padding-bottom: 4pt">Total</td><td style="padding-bottom: 4pt">&#160;</td> <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right">785,234</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td> <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right">4,093,847</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td></tr></table> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 11pt; text-align: justify; text-indent: -11pt"><font style="font: 10pt Times New Roman, Times, Serif"><b><i>Recent accounting pronouncements</i></b></font></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 11pt; text-align: justify; text-indent: -11pt"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><font style="font: 10pt Times New Roman, Times, Serif">In February 2016, the FASB issued ASU No. 2016-02, <i>Leases (Topic 842)</i>, which supersedes FASB Accounting Standards Codification ("ASC") Topic 840, Leases (Topic 840) and provides principles for the recognition, measurement, presentation and disclosure of leases for both lessees and lessors. The new standard requires lessees to apply a dual approach, classifying leases as either finance or operating leases based on the principle of whether or not the lease is effectively a financed purchase by the lessee. This classification will determine whether lease expense is recognized based on an effective interest method or on a straight-line basis over the term of the lease. A lessee is also required to record a right-of-use asset and a lease liability for all leases with a term of greater than twelve months regardless of classification. Leases with a term of twelve months or less will be accounted for similar to existing guidance for operating leases. The standard is effective for annual and interim periods beginning after December 15, 2018, with early adoption permitted upon issuance. The Company does not have any long-term leases, therefore the adoption of this standard on January 1, 2019 did not have an impact on the Company's condensed financial position and results of operations.</font></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><font style="font: 10pt Times New Roman, Times, Serif">In June 2018, the FASB issued ASU&#160;2018-07,&#160;<i>Compensation&#8212;Stock Compensation (Topic 718): Improvements to Non-employee Share-Based Payment Accounting</i>&#160;("ASU&#160;2018-07").&#160;ASU&#160;2018-07&#160;simplifies several aspects of the accounting for non-employee share-based payment transactions resulting from expanding the scope of Topic 718, Compensation&#8212;Stock Compensation, to include share-based payment transactions for acquiring goods and services from non-employees. ASU&#160;2018-07&#160;is effective for public business entities for fiscal years beginning after December 15, 2018, including interim periods within that fiscal year. The Company adopted ASU 2018-07 on January 1, 2019.&#160; Subsequent to the adoption of ASU 2018-07, the Company recognizes non-employee compensation costs over the requisite service period based on a measurement of fair value for each stock award.</font></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><font style="font: 10pt Times New Roman, Times, Serif">Management does not believe that any other recently issued, but not yet effective accounting pronouncements, if currently adopted, would have an effect on the Company's financial statements.</font></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;&#160;</p> <table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif"> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 88%">Cash</td><td style="width: 1%">&#160;</td> <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">4,092,706</td><td style="width: 1%; text-align: left">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left; padding-bottom: 1.5pt">Restricted cash</td><td style="padding-bottom: 1.5pt">&#160;</td> <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">200,000</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; padding-bottom: 4pt">Total cash and restricted cash</td><td style="font-weight: bold; padding-bottom: 4pt">&#160;</td> <td style="border-bottom: Black 4pt double; font-weight: bold; text-align: left">$</td><td style="border-bottom: Black 4pt double; font-weight: bold; text-align: right">4,292,706</td><td style="padding-bottom: 4pt; font-weight: bold; text-align: left">&#160;</td></tr></table> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><font style="font: 10pt Times New Roman, Times, Serif"></font></p> <table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif"> <tr style="vertical-align: bottom"> <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td> <td colspan="6" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">As of June 30</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr> <tr style="vertical-align: bottom"> <td style="font-weight: bold; text-align: left; border-bottom: Black 1.5pt solid">Potentially dilutive securities</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td> <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2019</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td> <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2018</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 76%; text-align: left">Series A Convertible Preferred Stock (Common Stock Equivalent)</td><td style="width: 1%">&#160;</td> <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">-</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td> <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">3,102,480</td><td style="width: 1%; text-align: left">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left">Warrants</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">767,870</td><td style="text-align: left">&#160;</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">991,367</td><td style="text-align: left">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; padding-bottom: 1.5pt">Non-vested restricted stock units</td><td style="padding-bottom: 1.5pt">&#160;</td> <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">17,364</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td> <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">-</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left; padding-bottom: 4pt">Total</td><td style="padding-bottom: 4pt">&#160;</td> <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right">785,234</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td> <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right">4,093,847</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td></tr></table> The Company, the University of Maryland, Baltimore ("UMD") and Isoprene Pharmaceuticals, Inc. ("Isoprene") entered into a commercial evaluation sublicense and option agreement. In consideration of the rights granted under the agreement, the Company paid an initial option and material access fee of $5,000 to UMD and $5,000 to Isoprene. 10000 <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><font style="font: 10pt Times New Roman, Times, Serif"></font></p> <table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif"> <tr style="vertical-align: bottom"> <td style="padding-left: 0.125in; text-indent: -0.125in">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td> <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Number of&#160;Units</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td> <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Weighted Average<br /> Grant Day<br /> Fair Value</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-left: 0.125in; text-indent: -0.125in">Nonvested at May 16, 2017 (inception)</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td> <td style="text-align: left">$</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="padding-left: 0.125in; text-indent: -0.125in">Nonvested at December 31, 2017</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 76%; text-align: left; padding-left: 0.25in; text-indent: -0.125in">Granted</td><td style="width: 1%">&#160;</td> <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">37,500</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td> <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">0.25</td><td style="width: 1%; text-align: left">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left; padding-bottom: 1.5pt; padding-left: 0.25in; text-indent: -0.125in">Vested</td><td style="padding-bottom: 1.5pt">&#160;</td> <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(15,970</td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td> <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">0.25</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-left: 0.125in; text-indent: -0.125in">Nonvested at December 31, 2018</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">21,530</td><td style="text-align: left">&#160;</td><td>&#160;</td> <td style="text-align: left">$</td><td style="text-align: right">0.25</td><td style="text-align: left">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left; padding-bottom: 1.5pt; padding-left: 0.25in; text-indent: -0.125in">Vested</td><td style="padding-bottom: 1.5pt">&#160;</td> <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(4,166</td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td> <td style="border-bottom: Black 1.5pt solid; text-align: left">$</td><td style="border-bottom: Black 1.5pt solid; text-align: right">0.25</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-bottom: 4pt; padding-left: 0.125in; text-indent: -0.125in">Nonvested at June 30, 2019</td><td style="padding-bottom: 4pt">&#160;</td> <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right">17,364</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td> <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">0.25</td></tr></table> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><font style="font: 10pt Times New Roman, Times, Serif"></font></p> <table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif"> <tr style="vertical-align: bottom"> <td style="font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td> <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Number of<br /> Warrants</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td> <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Weighted Average<br /> Exercise Price</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td> <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Total<br /> Intrinsic<br /> Value</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td> <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Weighted Average Remaining Contractual Life (in years)</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 52%">Outstanding as of December&#160;31, 2018</td><td style="width: 1%">&#160;</td> <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">991,367</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td> <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">1.00</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td> <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">-</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td> <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">5.4</td><td style="width: 1%; text-align: left">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="padding-left: 0.125in">Issued</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">66,333</td><td style="text-align: left">&#160;</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">5.28</td><td style="text-align: left">&#160;</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">94,731</td><td style="text-align: left">&#160;</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">4.9</td><td style="text-align: left">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; padding-bottom: 1.5pt; padding-left: 0.125in">Exercised</td><td style="padding-bottom: 1.5pt">&#160;</td> <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(289,830</td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td> <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">0.94</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td> <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">-</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td> <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">-</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="padding-bottom: 1.5pt">Outstanding as of June 30, 2019</td><td style="padding-bottom: 1.5pt">&#160;</td> <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">767,870</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td> <td style="border-bottom: Black 1.5pt solid; text-align: left">$</td><td style="border-bottom: Black 1.5pt solid; text-align: right">1.39</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td> <td style="border-bottom: Black 1.5pt solid; text-align: left">$</td><td style="border-bottom: Black 1.5pt solid; text-align: right">3,452,955</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td> <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">5.6</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-bottom: 4pt">Warrants exercisable as of June 30, 2019</td><td style="padding-bottom: 4pt">&#160;</td> <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right">767,870</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td> <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">1.39</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td> <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">3,452,955</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td> <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right">5.6</td></tr></table> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></p> <table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif"> <tr style="vertical-align: bottom"> <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td> <td colspan="6" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">For the Three Months&#160;Ended<br /> June 30,</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td> <td colspan="6" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">For the Six Months Ended<br /> June 30,</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr> <tr style="vertical-align: bottom"> <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td> <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2019</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td> <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2018</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td> <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2019</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td> <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2018</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 52%; text-align: left">Employee common stock awards</td><td style="width: 1%">&#160;</td> <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">-</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td> <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">117,500</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td> <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">-</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td> <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">132,500</td><td style="width: 1%; text-align: left">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left">Employee stock option awards</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">199,182</td><td style="text-align: left">&#160;</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Employee restricted stock awards</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">2,761</td><td style="text-align: left">&#160;</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">6,289</td><td style="text-align: left">&#160;</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left; padding-bottom: 1.5pt">Non-employee warrant awards</td><td style="padding-bottom: 1.5pt">&#160;</td> <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">84,605</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td> <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">&#160;</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td> <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">84,605</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td> <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">&#160;</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font-weight: bold; text-align: left; padding-bottom: 4pt">&#160;</td><td style="font-weight: bold; padding-bottom: 4pt">&#160;</td> <td style="border-bottom: Black 4pt double; font-weight: bold; text-align: left">$</td><td style="border-bottom: Black 4pt double; font-weight: bold; text-align: right">87,366</td><td style="padding-bottom: 4pt; font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; padding-bottom: 4pt">&#160;</td> <td style="border-bottom: Black 4pt double; font-weight: bold; text-align: left">$</td><td style="border-bottom: Black 4pt double; font-weight: bold; text-align: right">117,500</td><td style="padding-bottom: 4pt; font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; padding-bottom: 4pt">&#160;</td> <td style="border-bottom: Black 4pt double; font-weight: bold; text-align: left">$</td><td style="border-bottom: Black 4pt double; font-weight: bold; text-align: right">290,075</td><td style="padding-bottom: 4pt; font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; padding-bottom: 4pt">&#160;</td> <td style="border-bottom: Black 4pt double; font-weight: bold; text-align: left">$</td><td style="border-bottom: Black 4pt double; font-weight: bold; text-align: right">132,500</td><td style="padding-bottom: 4pt; font-weight: bold; text-align: left">&#160;</td></tr></table> 37500 0.25 -289830 0.94 P0Y 16333 16333 The Company issued 176,272 shares of common stock upon the cashless exercise of warrants to purchase up to 215,747 shares of common stock. Those warrants were issued by the Company to Laidlaw pursuant to the terms of its engagement letter with Laidlaw with respect to the private placement of its securities through October 2017 to December 2017. The Company issued 47,605 shares of common stock upon the cashless exercise of warrants to purchase up to 57,750 shares of common stock. <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><font style="font: 10pt Times New Roman, Times, Serif"></font></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><font style="font: 10pt Times New Roman, Times, Serif"><b>Note 5-Commitments and contingencies</b></font></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><font style="font: 10pt Times New Roman, Times, Serif"><b><i>Office lease</i></b></font></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><font style="font: 10pt Times New Roman, Times, Serif">The Company leases office space that commenced on July 15, 2017, for approximately $2,000 a month. Rent expense for the six months ended June 30, 2019 and 2018 was approximately $15,000 and $12,000, respectively. The term of the lease expires on July 31, 2020. In accordance with ASC 842, this lease meets the definition of a short-term lease and accordingly, is not subject to capitalization.</font></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><font style="font: 10pt Times New Roman, Times, Serif"><b><i>Litigation</i></b></font></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><font style="font: 10pt Times New Roman, Times, Serif">The Company is not a party to any material legal proceedings and is not aware of any pending or threatened claims. From time to time, the Company may be subject to various legal proceedings and claims that arise in the ordinary course of its business activities.</font></p> The Company leases office space that commenced on July 15, 2017, for approximately $2,000 a month. 239393 348951 239393 348951 27127 206671 212266 142280 4427813 503916 200000 1660 2268 4226153 501648 32127 206671 101320 12356 4092706 282621 4427813 503916 -6607957 -4511006 10795410 4665154 967 507 -1542 22 163 16333 16333 163 2 161 163 2 161 223877 223877 22 -22 22 -22 190180 false 001-38803 Yes NV Yes 1021554 1021417 137 1376500 4292706 20000 20000 <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><font style="font: 10pt Times New Roman, Times, Serif"><b>Note&#160;4-Stockholders&#8217; Equity&#160;</b></font></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><font style="font: 10pt Times New Roman, Times, Serif"><b>Preferred Stock</b></font></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><font style="font: 10pt Times New Roman, Times, Serif">The Company is authorized to issue up to 10,000,000 shares of preferred stock. This preferred stock may be issued in one or more series, and shall have such designations, preferences and relative, participating, optional or other special rights and qualifications, limitations or restrictions thereof as shall be determined at the time of issuance by its board of directors without further action by shareholders. As of June 30, 2019, 5,000,000 shares of the Company&#8217;s preferred stock has been designated as Series A Preferred Stock. At the time of the IPO, 3,102,480 shares of Series A Preferred Stock which were previously issued were converted into common stock and 1,897,520 shares of Series A Preferred Stock remained authorized.</font></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><font style="font: 10pt Times New Roman, Times, Serif"><b>Common Shares</b></font></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><font style="font: 10pt Times New Roman, Times, Serif"><b>&#160;</b></font></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><font style="font: 10pt Times New Roman, Times, Serif">On February 15, 2019, the Company announced the pricing of its initial public offering of 1,250,000 shares of its common stock at an initial offering price to the public of $5.60 per share. The Company issued an aggregate of 1,250,000 shares of common stock and received net proceeds of $5.8 million from the IPO.</font></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><font style="font: 10pt Times New Roman, Times, Serif"><b>Restricted Stock Awards</b></font></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><font style="font: 10pt Times New Roman, Times, Serif">A summary of the Company&#8217;s restricted stock awards activities under the Company&#8217;s 2018 Equity Incentive Plan (the &#8220;2018 Plan&#8221;) during the six months ended June 30, 2019 is as follows:</font></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><font style="font: 10pt Times New Roman, Times, Serif">&#160;&#160;</font></p> <table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif"> <tr style="vertical-align: bottom"> <td style="padding-left: 0.125in; text-indent: -0.125in">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td> <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Number of&#160;Units</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td> <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Weighted Average<br /> Grant Day<br /> Fair Value</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-left: 0.125in; text-indent: -0.125in">Nonvested at May 16, 2017 (inception)</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td> <td style="text-align: left">$</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="padding-left: 0.125in; text-indent: -0.125in">Nonvested at December 31, 2017</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 76%; text-align: left; padding-left: 0.25in; text-indent: -0.125in">Granted</td><td style="width: 1%">&#160;</td> <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">37,500</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td> <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">0.25</td><td style="width: 1%; text-align: left">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left; padding-bottom: 1.5pt; padding-left: 0.25in; text-indent: -0.125in">Vested</td><td style="padding-bottom: 1.5pt">&#160;</td> <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(15,970</td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td> <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">0.25</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-left: 0.125in; text-indent: -0.125in">Nonvested at December 31, 2018</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">21,530</td><td style="text-align: left">&#160;</td><td>&#160;</td> <td style="text-align: left">$</td><td style="text-align: right">0.25</td><td style="text-align: left">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left; padding-bottom: 1.5pt; padding-left: 0.25in; text-indent: -0.125in">Vested</td><td style="padding-bottom: 1.5pt">&#160;</td> <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(4,166</td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td> <td style="border-bottom: Black 1.5pt solid; text-align: left">$</td><td style="border-bottom: Black 1.5pt solid; text-align: right">0.25</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-bottom: 4pt; padding-left: 0.125in; text-indent: -0.125in">Nonvested at June 30, 2019</td><td style="padding-bottom: 4pt">&#160;</td> <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right">17,364</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td> <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">0.25</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td></tr> </table> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><font style="font: 10pt Times New Roman, Times, Serif">As of June 30, 2019, the Company had approximately $8,000 of unrecognized stock-based compensation expense which was related to restricted stock awards. The weighted average remaining contractual terms of unvested restricted stock awards is approximately 1.01 years at June 30, 2019.</font></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><font style="font: 10pt Times New Roman, Times, Serif"><b>Stock Options</b></font></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><font style="font: 10pt Times New Roman, Times, Serif">On March 6, 2019, the Company granted 50,000 options to purchase common stock of the Company to its CFO pursuant to the 2018 Plan. The aggregate grant date fair value of these options was approximately $0.2 million. The stock options vested in full upon grant.</font></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><font style="font: 10pt Times New Roman, Times, Serif"><b>Warrants</b></font></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><font style="font: 10pt Times New Roman, Times, Serif">A summary of warrant activity for the six months ended June 30, 2019 is presented below:</font></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><font style="font: 10pt Times New Roman, Times, Serif">&#160;&#160;</font></p> <table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif"> <tr style="vertical-align: bottom"> <td style="font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td> <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Number of<br /> Warrants</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td> <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Weighted Average<br /> Exercise Price</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td> <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Total<br /> Intrinsic<br /> Value</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td> <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Weighted Average Remaining Contractual Life (in years)</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 52%">Outstanding as of December&#160;31, 2018</td><td style="width: 1%">&#160;</td> <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">991,367</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td> <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">1.00</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td> <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">-</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td> <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">5.4</td><td style="width: 1%; text-align: left">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="padding-left: 0.125in">Issued</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">66,333</td><td style="text-align: left">&#160;</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">5.28</td><td style="text-align: left">&#160;</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">94,731</td><td style="text-align: left">&#160;</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">4.9</td><td style="text-align: left">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; padding-bottom: 1.5pt; padding-left: 0.125in">Exercised</td><td style="padding-bottom: 1.5pt">&#160;</td> <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(289,830</td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td> <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">0.94</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td> <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">-</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td> <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">-</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="padding-bottom: 1.5pt">Outstanding as of June 30, 2019</td><td style="padding-bottom: 1.5pt">&#160;</td> <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">767,870</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td> <td style="border-bottom: Black 1.5pt solid; text-align: left">$</td><td style="border-bottom: Black 1.5pt solid; text-align: right">1.39</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td> <td style="border-bottom: Black 1.5pt solid; text-align: left">$</td><td style="border-bottom: Black 1.5pt solid; text-align: right">3,452,955</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td> <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">5.6</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-bottom: 4pt">Warrants exercisable as of June 30, 2019</td><td style="padding-bottom: 4pt">&#160;</td> <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right">767,870</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td> <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">1.39</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td> <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">3,452,955</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td> <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right">5.6</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td></tr> </table> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><font style="font: 10pt Times New Roman, Times, Serif">On February 20, 2019, Laidlaw received five-year warrants to purchase 50,000 shares of the Company&#8217;s common stock at an exercise price of $7.00 per share. These warrants are not exercisable prior to August 13, 2019.</font></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;&#160;</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><font style="font: 10pt Times New Roman, Times, Serif">On April&#160;17, 2019, the Company entered into a Master Service Agreement (the &#8220;MSA&#8221;) with a consultant (the &#8220;Consultant&#8221;). In consideration for services provided by the Consultant, the Company issued the Consultant a two year warrant to purchase up to 50,000 shares of the Company&#8217;s common stock at an exercise price of $0.01 per share (the &#8220;Consultant Warrant&#8221;). On May 22, 2019, the Company and Consultant agreed to terminate the MSA and number of shares of the Company&#8217;s common stock issuable upon exercise of the Consultant Warrant was reduced to 16,333. On June 27, 2019, the Company issued 16,333 shares of common stock upon exercise of the Consultant Warrant which resulted in gross proceeds of approximately $163.</font></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><font style="font: 10pt Times New Roman, Times, Serif">On April 16, 2019, the Company issued 176,272 shares of common stock upon the cashless exercise of warrants to purchase up to 215,747 shares of common stock. Those warrants were issued by the Company to Laidlaw pursuant to the terms of its engagement letter with Laidlaw with respect to the private placement of its securities through October 2017 to December 2017.</font></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><font style="font: 10pt Times New Roman, Times, Serif">On June 6, 2019, the Company issued 47,605 shares of common stock upon the cashless exercise of warrants to purchase up to 57,750 shares of common stock.</font></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><font style="font: 10pt Times New Roman, Times, Serif">The Company has determined that the warrants should be accounted as a component of stockholders&#8217; equity.</font></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><font style="font: 10pt Times New Roman, Times, Serif"><b>Stock Based Compensation</b></font></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><font style="font: 10pt Times New Roman, Times, Serif">Stock-based compensation expense for the three and six months ended June 30, 2019 and 2018 was as follows:</font></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><font style="font: 10pt Times New Roman, Times, Serif">&#160;&#160;</font></p> <table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif"> <tr style="vertical-align: bottom"> <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td> <td colspan="6" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">For the Three Months&#160;Ended<br /> June 30,</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td> <td colspan="6" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">For the Six Months Ended<br /> June 30,</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr> <tr style="vertical-align: bottom"> <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td> <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2019</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td> <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2018</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td> <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2019</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td> <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2018</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 52%; text-align: left">Employee common stock awards</td><td style="width: 1%">&#160;</td> <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">-</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td> <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">117,500</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td> <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">-</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td> <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">132,500</td><td style="width: 1%; text-align: left">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left">Employee stock option awards</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">199,182</td><td style="text-align: left">&#160;</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Employee restricted stock awards</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">2,761</td><td style="text-align: left">&#160;</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">6,289</td><td style="text-align: left">&#160;</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left; padding-bottom: 1.5pt">Non-employee warrant awards</td><td style="padding-bottom: 1.5pt">&#160;</td> <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">84,605</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td> <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">&#160;</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td> <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">84,605</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td> <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">&#160;</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font-weight: bold; text-align: left; padding-bottom: 4pt">&#160;</td><td style="font-weight: bold; padding-bottom: 4pt">&#160;</td> <td style="border-bottom: Black 4pt double; font-weight: bold; text-align: left">$</td><td style="border-bottom: Black 4pt double; font-weight: bold; text-align: right">87,366</td><td style="padding-bottom: 4pt; font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; padding-bottom: 4pt">&#160;</td> <td style="border-bottom: Black 4pt double; font-weight: bold; text-align: left">$</td><td style="border-bottom: Black 4pt double; font-weight: bold; text-align: right">117,500</td><td style="padding-bottom: 4pt; font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; padding-bottom: 4pt">&#160;</td> <td style="border-bottom: Black 4pt double; font-weight: bold; text-align: left">$</td><td style="border-bottom: Black 4pt double; font-weight: bold; text-align: right">290,075</td><td style="padding-bottom: 4pt; font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; padding-bottom: 4pt">&#160;</td> <td style="border-bottom: Black 4pt double; font-weight: bold; text-align: left">$</td><td style="border-bottom: Black 4pt double; font-weight: bold; text-align: right">132,500</td><td style="padding-bottom: 4pt; font-weight: bold; text-align: left">&#160;</td></tr> </table> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><font style="font: 10pt Times New Roman, Times, Serif">In addition, the Company recorded $0 and $13,000 of stock issued for research and development services for the three months ended June 30, 2019 and 2018, respectively, and $0 and $24,000 of stock issued for research and development services for the six months ended June 30, 2019 and 2018, respectively.</font></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><font style="font: 10pt Times New Roman, Times, Serif"></font></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Employee related stock based compensation&#160;is recognized as &#8220;compensation and related expenses&#8221; and non-employee related stock based compensation is recognized as &#8220;professional fees&#8221; in the condensed statements of operations.</p> 4292706 282621 1466824 1230440 <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><font style="font: 10pt Times New Roman, Times, Serif"><b></b></font></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><font style="font: 10pt Times New Roman, Times, Serif"><b>Note&#160;1-Organization and description of business operations</b></font></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><font style="font: 10pt Times New Roman, Times, Serif">Hoth Therapeutics,&#160;Inc. (the "Company") was incorporated under the laws of the State of Nevada on May&#160;16, 2017. The Company's primary asset is a sublicense agreement with Chelexa Biosciences, Inc. ("Chelexa") pursuant to which Chelexa has granted the Company an exclusive sublicense to use its BioLexa Platform, a proprietary, patented, drug compound platform developed at the University of Cincinnati. The license enables the Company to develop the platform for all indications in humans. The Company's initial focus will be on the treatment of eczema. The BioLexa Platform combines a U.S. Food and Drug Administration ("FDA") approved zinc chelator with one or more approved antibiotics in a topical dosage form to address unchecked eczema flare-ups by preventing the formation of infectious biofilms and the resulting clogging of sweat ducts which trigger symptoms. To the Company's knowledge, it is the first product candidate intended to prevent the symptom triggering flare-ups rather than simply treating symptoms when they occur.</font></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><font style="font: 10pt Times New Roman, Times, Serif">On May 26, 2017, the Company entered into a sublicense agreement with Chelexa, as amended on August 22, 2018 and August 29, 2018, pursuant to which Chelexa granted the Company an exclusive sublicense to make, use, have made, import, offer for sale, and sell products based upon or involving the use of (i) topical compositions comprising a zinc chelator and gentamicin and (ii) zinc chelators to inhibit biofilm formation (the "BioLexa Platform" or "BioLexa"), which rights were originally granted to Chelexa pursuant to an exclusive license agreement with the University of Cincinnati. In addition, Chelexa granted the Company the right to issue exclusive and nonexclusive sublicenses (with the right to further sublicense to third parties) to make, use, have made, import, offer for sale, and sell products based upon the BioLexa Platform.</font></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><font style="font: 10pt Times New Roman, Times, Serif"><b><i>&#160;</i></b></font></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><font style="font: 10pt Times New Roman, Times, Serif"><b><i>Company's IPO</i></b></font></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><font style="font: 10pt Times New Roman, Times, Serif"><b><i>&#160;</i></b></font></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><font style="font: 10pt Times New Roman, Times, Serif">On February 15, 2019, the Company announced the pricing of its initial public offering (the "IPO") of 1,250,000 shares of its common stock at an initial offering price to the public of $5.60 per share.&#160;&#160;In addition, the Company granted the underwriters a 45-day option to purchase up to an additional 187,500 shares of common stock at the initial public offering price, less the underwriting discount, to cover over-allotments (the "Green-shoe"), if any. The underwriters did not exercise any portion of the Green-shoe. Therefore, the Company issued 1,250,000 shares of common stock and received net proceeds of $5.8 million from the IPO.</font></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><font style="font: 10pt Times New Roman, Times, Serif">The Company's common stock commenced trading on The Nasdaq Capital Market, on February 15, 2019 under the ticker symbol "HOTH".&#160;The IPO closed on February 20, 2019.</font></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><font style="font: 10pt Times New Roman, Times, Serif"><b><i>&#160;</i></b></font></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><font style="font: 10pt Times New Roman, Times, Serif">On February 14, 2019, the Company entered into an underwriting agreement with Laidlaw &#38; Co. (UK) Ltd. ("Laidlaw") pursuant to which the Company paid Laidlaw a fee in the amount of 7% of the gross proceeds of the IPO, or $490,000. The Company also reimbursed Laidlaw for certain out-of-pocket expenses, including the fees and disbursements of their counsel, up to an aggregate of $0.2 million.&#160;In addition, Laidlaw received five-year warrants to purchase 50,000 shares of common stock of the Company at an exercise price of $7.00 per share.</font></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><font style="font: 10pt Times New Roman, Times, Serif"><b><i>&#160;</i></b></font></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><font style="font: 10pt Times New Roman, Times, Serif"><b><i>Liquidity and capital resources</i></b></font></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Accounting Standards Update, or ASU, No. 2014-15, Presentation of Financial Statements - Going Concern, requires management to evaluate the Company's ability to continue as a going concern one year beyond the filing date of the given financial statements. This evaluation requires management to perform two steps. First, management must evaluate whether there are conditions and events that raise substantial doubt about the entity's ability to continue as a going concern. Second, if management concludes that substantial doubt is raised, management is required to consider whether it has plans in place to alleviate that doubt. Disclosures in the notes to the financial statements are required if management concludes that substantial doubt exists or that its plans alleviate the substantial doubt that was raised.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><font style="font: 10pt Times New Roman, Times, Serif"></font></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><font style="font: 10pt Times New Roman, Times, Serif">The Company has incurred substantial operating losses since inception and expects to continue to incur significant operating losses for the foreseeable future and may never become profitable. As of June 30, 2019, the Company had cash of approximately $4.1 million, working capital of approximately $4.0 million and an accumulated deficit of approximately $6.6 million.</font></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><font style="font: 10pt Times New Roman, Times, Serif">The Company has funded its operations from proceeds from the sale of equity and debt securities. The Company will require significant additional capital to make the investments it needs to execute its longer-term business plan. The Company's ability to successfully raise sufficient funds through the sale of debt or equity securities when needed is subject to many risks and uncertainties and, even if it were successful, future equity issuances would result in dilution to its existing stockholders and any future debt securities may contain covenants that limit the Company's operations or ability to enter into certain transactions.</font></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><font style="font: 10pt Times New Roman, Times, Serif">The proceeds from the IPO and the current cash are sufficient to fund operations for at least the next 12 months; however, the Company will need to raise additional funding through strategic relationships, public or private equity or debt financings, grants or other arrangements to develop and seek regulatory approvals for the Company's existing and new product candidates. If such funding is not available, or not available on terms acceptable to the Company, the Company's current development plan and plans for expansion of its general and administrative infrastructure may be curtailed.</font></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><font style="font: 10pt Times New Roman, Times, Serif"><b>Note&#160;3 - License agreements</b></font></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 13.2pt; text-align: justify; text-indent: -13.2pt"><font style="font: 10pt Times New Roman, Times, Serif"><b>&#160;</b></font></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 13.2pt; text-align: justify; text-indent: -13.2pt"><font style="font: 10pt Times New Roman, Times, Serif"><b>Chelexa BioSciences, Inc.</b></font></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><font style="font: 10pt Times New Roman, Times, Serif"></font></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">On May 26, 2017, the Company entered into a sublicense agreement with&#160; Chelexa BioSciences, Inc.&#160;(&#8220;Chelexa&#8221;) as amended on August 22, 2018 and August 29, 2018. The term of such agreement will expire on the later of April 16, 2034 and the last to expire patent in the patent rights granted to the Company (the &#8220;Term&#8221;). The Company shall, in its sole discretion, have the first right of refusal to renew the Term. The Company is subject to total milestone payments of $3.5 million and has agreed to fund all development and commercialization costs related to the licensed products. In addition, during the Term, the Company shall pay royalty payments which shall be based on a percentage of annual aggregate net sales.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><font style="font: 10pt Times New Roman, Times, Serif"></font></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 13.2pt; text-align: justify; text-indent: -13.2pt"><font style="font: 10pt Times New Roman, Times, Serif"><b>University of Maryland and Isoprene Pharmaceuticals, Inc.</b></font></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 13.2pt; text-align: justify; text-indent: -13.2pt"><font style="font: 10pt Times New Roman, Times, Serif"><b>&#160;</b></font></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><font style="font: 10pt Times New Roman, Times, Serif"></font></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">On March 8, 2019, the Company, the University of Maryland, Baltimore (&#8220;UMD&#8221;) and Isoprene Pharmaceuticals, Inc. (&#8220;Isoprene&#8221;) entered into a commercial evaluation sublicense and option agreement. In consideration of the rights granted under the agreement, the Company paid an initial option and material access fee of $5,000 to UMD and $5,000 to Isoprene. In the event that Isoprene enters into a master license agreement with UMD (the &#8220;MLA&#8221;), UMD shall permit Isoprene to grant an exclusive option to the Company to negotiate and obtain an exclusive sublicensable, worldwide royalty-bearing license to the subject technology (the &#8220;Isoprene-Hoth Option&#8221;); provided, however, in the event Isoprene does not enter into the MLA, UMD may grant the Company an option to negotiate and obtain an exclusive sublicensable, worldwide royalty-bearing license to the subject technology (the &#8220;UMD-Hoth Option&#8221;). If the Company exercises the Isoprene-Hoth Option, it shall pay Isoprene an option exercise fee of $20,000. If the Company exercises the UMD-Hoth Option, it shall pay UMD an option exercise fee of $20,000.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><font style="font: 10pt Times New Roman, Times, Serif"></font></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 13.2pt; text-align: justify; text-indent: -13.2pt"><font style="font: 10pt Times New Roman, Times, Serif"><b>Zyl&#246; Therapeutics Inc.</b></font></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 13.2pt; text-align: justify; text-indent: -13.2pt"><font style="font: 10pt Times New Roman, Times, Serif"><b>&#160;</b></font></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><font style="font: 10pt Times New Roman, Times, Serif">On May 10, 2019, the Company and Zyl&#246; Therapeutics Inc. (&#8220;Zyl&#246;&#8221;) entered into a term sheet (the &#8220;Zyl&#246; Term Sheet&#8221;) with respect to the potential development and commercialization of certain licensed products. As of June 30, 2019, the Company paid Zyl&#246; $10,000 upon execution of the Zyl&#246; Term Sheet.</font></p> 200000 9669644 <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><font style="font: 10pt Times New Roman, Times, Serif"><b>Note&#160;2-Significant accounting policies</b></font></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 11pt; text-align: justify; text-indent: -11pt"><font style="font: 10pt Times New Roman, Times, Serif"><b><i>Basis of presentation</i></b></font></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 11pt; text-align: justify; text-indent: -11pt"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><font style="font: 10pt Times New Roman, Times, Serif">The accompanying unaudited interim condensed financial statements have been prepared in accordance with generally accepted accounting principles in the United States of America (&#8220;GAAP&#8221;) for interim financial information and the instructions to Form 10-Q and Article 8 of Regulation S-X. Accordingly, they do not include all of the information and footnotes required by GAAP for complete financial statements. In the opinion of management, the unaudited interim condensed financial statements reflect all adjustments, which include only normal recurring adjustments necessary for the fair statement of the balances and results for the periods presented. Certain information and footnote disclosures normally included in the Company&#8217;s annual financial statements prepared in accordance with GAAP have been condensed or omitted. These condensed financial statement results are not necessarily indicative of results to be expected for the full fiscal year or any future period.&#160;The accompanying unaudited condensed financial statements should be read in conjunction with the audited financial statements and notes thereto included in the Company&#8217;s Annual Report on Form 10-K filed by the Company with the SEC on April 1, 2019.</font></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 11pt; text-align: justify; text-indent: -11pt"><font style="font: 10pt Times New Roman, Times, Serif"><b><i>Use of estimates</i></b></font></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><font style="font: 10pt Times New Roman, Times, Serif">The preparation of financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of expenses during the reporting periods. The most significant estimates in the Company&#8217;s financial statements relate to the valuation of preferred and common stock, stock-based compensation and the valuation allowance of deferred tax assets resulting from net operating losses. These estimates and assumptions are based on current facts, historical experience and various other factors believed to be reasonable under the circumstances, the results of which form the basis for making judgments about the carrying values of assets and liabilities and the recording of expenses that are not readily apparent from other sources. Actual results may differ materially and adversely from these estimates. To the extent there are material differences between the estimates and actual results, the Company&#8217;s future results of operations will be affected.</font></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><font style="font: 10pt Times New Roman, Times, Serif"><b><i>Significant Accounting Policies&#160;</i></b></font></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 44pt"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><font style="font: 10pt Times New Roman, Times, Serif">There have been no material changes to the Company&#8217;s significant accounting policies previously disclosed in the Company&#8217;s Annual Report on Form 10-K for the fiscal year ended December 31, 2018 as filed with the Securities and Exchange Commission (&#8220;SEC&#8221;) on April 1, 2019.</font></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><font style="font: 10pt Times New Roman, Times, Serif"><b><i>&#160;</i></b></font></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><font style="font: 10pt Times New Roman, Times, Serif"><b><i>Restricted Cash</i></b></font></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><font style="font: 10pt Times New Roman, Times, Serif">In November 2016, the Financial Accounting Standards Board (&#8220;FASB&#8221;) issued <i>Accounting Standards Update </i>(&#8220;ASU<i>&#8221;) No.&#160;2016-18,&#160;Statement of Cash Flows (Topic 230): Restricted Cash&#160;</i>(&#8220;ASU&#160;2016-18&#8221;)<i>,</i>&#160;which clarifies the presentation of restricted cash in the statements of cash flows. Under ASU&#160;2016-18,&#160;restricted cash is included with cash and cash equivalents when reconciling the beginning-of-period and end-of-period total amounts shown on the statements of cash flows. The Company adopted ASU&#160;2016-18&#160;during the six months ended June 30, 2019 on a retrospective basis. The following is a summary of the Company&#8217;s cash and restricted cash total as presented in the consolidated statements of cash flows for the six months ended June 30, 2019:</font></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><font style="font: 10pt Times New Roman, Times, Serif">&#160;&#160;</font></p> <table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif"> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 88%">Cash</td><td style="width: 1%">&#160;</td> <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">4,092,706</td><td style="width: 1%; text-align: left">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left; padding-bottom: 1.5pt">Restricted cash</td><td style="padding-bottom: 1.5pt">&#160;</td> <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">200,000</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; padding-bottom: 4pt">Total cash and restricted cash</td><td style="font-weight: bold; padding-bottom: 4pt">&#160;</td> <td style="border-bottom: Black 4pt double; font-weight: bold; text-align: left">$</td><td style="border-bottom: Black 4pt double; font-weight: bold; text-align: right">4,292,706</td><td style="padding-bottom: 4pt; font-weight: bold; text-align: left">&#160;</td></tr> </table> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><font style="font: 10pt Times New Roman, Times, Serif"><b><i>&#160;</i></b></font></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><font style="font: 10pt Times New Roman, Times, Serif"><b><i></i></b></font></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The $0.2 million restricted cash has been deposited into a third-party escrow account in order to provide a source of funding for certain indemnification obligations the Company has pursuant to its Qualified Independent Underwriter Engagement Agreement.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><font style="font: 10pt Times New Roman, Times, Serif"><b><i>&#160;</i></b></font></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><font style="font: 10pt Times New Roman, Times, Serif"><b><i>Stock-based compensation</i></b></font></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><font style="font: 10pt Times New Roman, Times, Serif">The Company expenses stock-based compensation to employees and non-employees over the requisite service period based on the estimated grant-date fair value of the awards. Stock-based awards with graded-vesting schedules are recognized on a straight-line basis over the requisite service period for each separately vesting portion of the award. The Company records the expense for stock-based compensation awards subject to performance-based milestone vesting over the remaining service period when management determines that achievement of the milestone is probable. Management evaluates when the achievement of a performance-based milestone is probable based on the expected satisfaction of the performance conditions at each reporting date. All stock-based compensation costs are recorded in general and administrative or research and development costs in the statements of operations based upon the underlying employees&#8217; or non-employees&#8217; roles within the Company.</font></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>&#160;</i></b>&#160;</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><font style="font: 10pt Times New Roman, Times, Serif"><b><i>Net loss per share</i></b></font></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><font style="font: 10pt Times New Roman, Times, Serif"><b><i>&#160;</i></b></font></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><font style="font: 10pt Times New Roman, Times, Serif">Net loss per share is computed by dividing net loss by the weighted average number of common stock outstanding during the period. Since the Company had a net loss in the periods presented, basic and diluted net loss per common share are the same. The following were excluded from the computation of diluted shares outstanding due to the losses for each period presented, as they would have had an anti-dilutive impact on the Company&#8217;s net loss:</font></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><font style="font: 10pt Times New Roman, Times, Serif">&#160;&#160;</font></p> <table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif"> <tr style="vertical-align: bottom"> <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td> <td colspan="6" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">As of June 30</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr> <tr style="vertical-align: bottom"> <td style="font-weight: bold; text-align: left; border-bottom: Black 1.5pt solid">Potentially dilutive securities</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td> <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2019</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td> <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2018</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 76%; text-align: left">Series A Convertible Preferred Stock (Common Stock Equivalent)</td><td style="width: 1%">&#160;</td> <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">-</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td> <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">3,102,480</td><td style="width: 1%; text-align: left">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left">Warrants</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">767,870</td><td style="text-align: left">&#160;</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">991,367</td><td style="text-align: left">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; padding-bottom: 1.5pt">Non-vested restricted stock units</td><td style="padding-bottom: 1.5pt">&#160;</td> <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">17,364</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td> <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">-</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left; padding-bottom: 4pt">Total</td><td style="padding-bottom: 4pt">&#160;</td> <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right">785,234</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td> <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right">4,093,847</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td></tr> </table> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 11pt; text-align: justify; text-indent: -11pt"><font style="font: 10pt Times New Roman, Times, Serif"><b><i>Recent accounting pronouncements</i></b></font></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 11pt; text-align: justify; text-indent: -11pt"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><font style="font: 10pt Times New Roman, Times, Serif">In February 2016, the FASB issued ASU No. 2016-02, <i>Leases (Topic 842)</i>, which supersedes FASB Accounting Standards Codification (&#8220;ASC&#8221;) Topic 840, Leases (Topic 840) and provides principles for the recognition, measurement, presentation and disclosure of leases for both lessees and lessors. The new standard requires lessees to apply a dual approach, classifying leases as either finance or operating leases based on the principle of whether or not the lease is effectively a financed purchase by the lessee. This classification will determine whether lease expense is recognized based on an effective interest method or on a straight-line basis over the term of the lease. A lessee is also required to record a right-of-use asset and a lease liability for all leases with a term of greater than twelve months regardless of classification. Leases with a term of twelve months or less will be accounted for similar to existing guidance for operating leases. The standard is effective for annual and interim periods beginning after December 15, 2018, with early adoption permitted upon issuance. The Company does not have any long-term leases, therefore the adoption of this standard on January 1, 2019 did not have an impact on the Company&#8217;s condensed financial position and results of operations.</font></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><font style="font: 10pt Times New Roman, Times, Serif">In June 2018, the FASB issued ASU&#160;2018-07,&#160;<i>Compensation&#8212;Stock Compensation (Topic 718): Improvements to Non-employee Share-Based Payment Accounting</i>&#160;(&#8220;ASU&#160;2018-07&#8221;).&#160;ASU&#160;2018-07&#160;simplifies several aspects of the accounting for non-employee share-based payment transactions resulting from expanding the scope of Topic 718, Compensation&#8212;Stock Compensation, to include share-based payment transactions for acquiring goods and services from non-employees. ASU&#160;2018-07&#160;is effective for public business entities for fiscal years beginning after December 15, 2018, including interim periods within that fiscal year. The Company adopted ASU 2018-07 on January 1, 2019.&#160; Subsequent to the adoption of ASU 2018-07, the Company recognizes non-employee compensation costs over the requisite service period based on a measurement of fair value for each stock award.</font></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><font style="font: 10pt Times New Roman, Times, Serif">Management does not believe that any other recently issued, but not yet effective accounting pronouncements, if currently adopted, would have an effect on the Company&#8217;s financial statements.</font></p> EX-101.SCH 7 hoth-20190630.xsd XBRL SCHEMA FILE 00000001 - Document - Document and Entity Information link:presentationLink link:calculationLink link:definitionLink 00000002 - Statement - Condensed Balance Sheets link:presentationLink link:calculationLink link:definitionLink 00000003 - Statement - Condensed Balance Sheets (Parenthetical) link:presentationLink link:calculationLink link:definitionLink 00000004 - Statement - Condensed Statements of Operations (Unaudited) link:presentationLink link:calculationLink link:definitionLink 00000005 - Statement - Condensed Statements of Changes in Stockholders' Equity (Unaudited) link:presentationLink link:calculationLink link:definitionLink 00000006 - Statement - Condensed Statements of Changes in Stockholders' Equity (Unaudited) (Parenthetical) link:presentationLink link:calculationLink link:definitionLink 00000007 - Statement - Condensed Statements of Cash Flows (Unaudited) link:presentationLink link:calculationLink link:definitionLink 00000008 - Disclosure - Organization and Description of Business Operations link:presentationLink link:calculationLink link:definitionLink 00000009 - Disclosure - Significant Accounting Policies link:presentationLink link:calculationLink link:definitionLink 00000010 - Disclosure - License Agreements link:presentationLink link:calculationLink link:definitionLink 00000011 - Disclosure - Stockholders' Equity link:presentationLink link:calculationLink link:definitionLink 00000012 - Disclosure - Commitments and Contingencies link:presentationLink link:calculationLink link:definitionLink 00000013 - Disclosure - Significant Accounting Policies (Policies) link:presentationLink link:calculationLink link:definitionLink 00000014 - Disclosure - Significant Accounting Policies (Tables) link:presentationLink link:calculationLink link:definitionLink 00000015 - Disclosure - Stockholders' Equity (Tables) link:presentationLink link:calculationLink link:definitionLink 00000016 - Disclosure - Organization and Description of Business Operations (Details) link:presentationLink link:calculationLink link:definitionLink 00000017 - Disclosure - Significant Accounting Policies (Details) link:presentationLink link:calculationLink link:definitionLink 00000018 - Disclosure - Significant Accounting Policies (Details 1) link:presentationLink link:calculationLink link:definitionLink 00000019 - Disclosure - Significant Accounting Policies (Details Textual) link:presentationLink link:calculationLink link:definitionLink 00000020 - Disclosure - License Agreements (Details) link:presentationLink link:calculationLink link:definitionLink 00000021 - Disclosure - Stockholders' Equity (Details) link:presentationLink link:calculationLink link:definitionLink 00000022 - Disclosure - Stockholders' Equity (Details 1) link:presentationLink link:calculationLink link:definitionLink 00000023 - Disclosure - Stockholders' Equity (Details 2) link:presentationLink link:calculationLink link:definitionLink 00000024 - Disclosure - Stockholders' Equity (Details Textual) link:presentationLink link:calculationLink link:definitionLink 00000025 - Disclosure - Commitments and Contingencies (Details) link:presentationLink link:calculationLink link:definitionLink EX-101.CAL 8 hoth-20190630_cal.xml XBRL CALCULATION FILE EX-101.DEF 9 hoth-20190630_def.xml XBRL DEFINITION FILE EX-101.LAB 10 hoth-20190630_lab.xml XBRL LABEL FILE Equity Components [Axis] Common Stock Additional Paid-in Capital Accumulated Deficit Antidilutive Securities [Axis] Series A Convertible Preferred Stock (Common Stock Equivalent) [Member] Warrants [Member] Non-vested restricted stock units [Member] Title of Individual [Axis] Chelexa BioSciences, Inc. [Member] Convertible Preferred Stock Award Type [Axis] Restricted Stock Units (RSUs) [Member] Employee common stock awards [Member] Employee restricted stock awards [Member] Sale of Stock [Axis] Initial public offering [Member] Statement Class Of Stock [Axis] Series A Preferred Stock Employee stock option awards [Member] Initial Public Offering [Member] 2018 Equity Incentive Plan [Member] Zylö Therapeutics Inc.[Member] Non-employee warrant awards [Member] Convertible Preferred Stock Additional Paid-In Capital Retained Earnings / Accumulated Deficit Isoprene-Hoth Option [Member] UMD-Hoth Option [Member] Document And Entity Information Entity Registrant Name Entity Central Index Key Amendment Flag Current Fiscal Year End Date Document Type Document Period End Date Document Fiscal Period Focus Document Fiscal Year Focus Entity Current Reporting Status Entity Filer Category Entity Ex Transition Period Entity Small Business Entity Shell Company Entity Emerging Growth Company Entity Common Stock, Shares Outstanding Entity File Number Entity Incorporation State Country Code Entity Interactive Data Current Statement [Table] Statement [Line Items] Class of Stock [Axis] ASSETS Current assets Cash Prepaid expenses Deferred offering cost Total current assets Property and equipment, net Restricted cash Total assets LIABILITIES AND STOCKHOLDERS' EQUITY Current liabilities Accounts payable Accrued expenses Total current liabilities Total liabilities Commitments and contingencies Stockholders' equity Preferred stock value Common stock, 0.0001 par value, 75,000,000 shares authorized at June 30, 2019 and December 31, 2018; 9,668,256 and 5,071,400 shares issued and outstanding at June 30, 2019 and December 31, 2018, respectively Additional paid-in-capital Accumulated deficit Total stockholders' equity Total liabilities and stockholders' equity Preferred stock, par value Preferred stock, shares authorized Preferred stock, shares issued Preferred stock, shares outstanding Common stock, par value Common stock, shares authorized Common stock, shares issued Common stock, shares outstanding Income Statement [Abstract] Operating costs and expenses Research and development Research and development - license acquired Compensation and related expenses (including stock-based compensation) Professional fees Rent Other expenses Total operating expenses Loss from operations Net loss Weighted average number of common shares outstanding, basic and diluted Net loss per share, basic and diluted Balance Balance, shares Conversion of Preferred stock to common stock upon completion of the IPO Conversion of Preferred stock to common stock upon completion of the IPO, shares Issuance common stock in the IPO, net of offering cost Issuance common stock in the IPO, net of offering cost, shares Cashless warrant exercise Cashless warrant exercise, shares Warrant exercise Warrant exercise, shares Stock-based compensation Stock-based compensation, shares Stock issued for research and development Stock issued for research and development, shares Stock issued for acquired license Stock issued for acquired license, shares Issuance of Series A Convertible Preferred Stock and warrants for cash in an offering (net of offering costs of 190,180) Issuance of Series A Convertible Preferred Stock and warrants for cash in an offering (net of offering costs of 190,180), shares Warrant value related to Issuance of Series A Convertible Preferred Stock Net loss Balance Balance, shares Statement of Stockholders' Equity [Abstract] Net of offering costs Statement of Cash Flows [Abstract] Cash flows from operating activities Adjustments to reconcile net loss to net cash used in operating activities: Depreciation expense Research and development-acquired license, expensed Stock issued for research and development Stock-based compensation Changes in assets and liabilities: Prepaid expenses Accrued salaries and benefits Accounts payable Net cash used in operating activities Cash flows from investing activities Purchase of research and development licenses Net cash used in investing activities Cash flows from financing activities Proceeds from issuance of Series A Convertible Preferred Stock and warrants for cash in an offering, net Cash from issuance of common stock in the IPO, net of offering cost Proceeds from exercise of warrants Net cash provided by financing activities Net increase in cash Cash and restricted cash, beginning of period Cash and restricted cash, end of period Non-cash investing and financing activities Conversion of preferred stock to common stock upon completion of the IPO Common stock issued for acquired license Cashless warrant exercise Unpaid offering cost included in accrued expenses Organization, Consolidation and Presentation of Financial Statements [Abstract] Organization and description of business operations Accounting Policies [Abstract] Significant accounting policies License Agreement [Abstract] License agreements Equity [Abstract] Stockholders' Equity Commitments and Contingencies Disclosure [Abstract] Commitments and contingencies Basis of presentation Use of estimates Significant Accounting Policies Restricted Cash Stock-based compensation Net loss per share Recent accounting pronouncements Schedule of consolidated statements of cash flows Schedule of anti-dilutive impact on net loss restricted stock awards activities under the Company's 2018 Equity Incentive Plan Schedule of warrant activity Schedule of Stock-based compensation expense Organization and Description of Business Operations (Textual) Cash Working capital Common stock issued for initial public offering price Additional shares of common stock Net proceeds from initial public offering Initial offering price per share Description of underwriting agreement Significant Accounting Policies Cash Restricted cash Total cash and restricted cash Potentially dilutive securities Total Significant Accounting Policies (Textual) Escrow deposit Zylö Therapeutics Inc. [Member] License Agreements (Textual) Milestone payments Commercial evaluation sublicense and option agreement description Development and commercialization expenses Option exercise fee Restricted Stock Awards [Member] Number of Units Number of Shares, Nonvested Beginning Balance Number of Shares, Granted Number of Shares, Vested Number of Shares, Nonvested Ending Balance Weighted Average Grant Day Fair Value Weighted average grant day fair value, Nonvested Beginning balance Weighted average grant day fair value, Granted Weighted average grant day fair value, Vested Weighted average grant day fair value, Nonvested Ending balance Number of Warrants Outstanding Issued Exercised Outstanding Warrants exercisable Weighted Average Exercise Price Outstanding Issued Exercised Outstanding Warrants exercisable Total Intrinsic Value Outstanding Issued Exercised Outstanding Warrants exercisable Weighted Average Remaining Contractual Life (in years) Outstanding Issued Exercised Outstanding Warrants exercisable Stockholders' Equity (Textual) Options granted Aggregate grant fair value Price per share Warrants to purchase of common stock shares Warrants exercise price Issuance of shares of common stock, shares Shares of common stock Unrecognized stock-based compensation expense Weighted average remaining contractual terms of unvested restricted stock Preferred stock designated Preferred stock converted into common stock Preferred Shares remain authorized Net proceeds received Exercise warrant reduced Common stock issued, description Commitments and Contingencies (Textual) Lease agreement terms, description Rent expense Lease expires date Amount of compensation and related expenses (including stock-based compensation) The amount of conversion of Preferred stock to common stock upon completion of the IPO. Conversion of Preferred stock to common stock upon completion of the IPO. Conversion of Preferred stock to common stock upon completion of the IPO, shares. Description of underwriting agreement. The amount of common stock issued for acquired license. Preferred Shares remain authorized. Preferred stock converted into common stock. Preferred stock designated. The cash inflow from issuance of Series A Convertible Preferred Stock and warrants for cash in an offering, net. Amount of rent expenses. The aggregate costs incurred research and development - license acquired. Research and development-stock issued for acquired license, expensed. Significant Accounting Policies [Abstract] Disclosure of accounting policy for significant accounting policies. Number of shares of stock issued during the period as part of a transaction to research and development. Amount of research and development. Research and development-stock issued for acquired license, expensed. The amount of unpaid offering cost included in accrued expenses. Warrant value related to Issuance of convertible preferred stock. Warrants to purchase of common stock shares Shares of Additional shares of common stock. Amount of Development and commercialization expenses. Weighted Average Remaining Contractual Life exercised Exercise warrant reduced. Common stock issued, description. Cashless warrant exercise. Cashless warrant exercise Cashless warrant exercise, shares Amount of Warrant exercise. Warrant exercise, shares. Document and Entity Information Convertible Preferred Stock [Member] Assets, Current Assets Liabilities, Current Liabilities Stockholders' Equity Attributable to Parent Liabilities and Equity Operating Expenses Operating Income (Loss) Shares, Outstanding StockIssuedForResearchAndDevelopment Share-based Payment Arrangement, Noncash Expense Increase (Decrease) in Prepaid Expense Increase (Decrease) in Accounts Payable Net Cash Provided by (Used in) Operating Activities Payments to Acquire in Process Research and Development Net Cash Provided by (Used in) Investing Activities Net Cash Provided by (Used in) Financing Activities Cash and Cash Equivalents, Period Increase (Decrease) Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents CashlessWarrantExercise Commitments and Contingencies Disclosure [Text Block] Share-based Payment Arrangement, Director [Policy Text Block] Cash [Default Label] Restricted Cash [Default Label] Restricted Cash Equivalents Restricted Cash and Cash Equivalents Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Number Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Vested in Period Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Exercise Price Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price Share-based Compensation Arrangements by Share-based Payment Award, Options, Exercises in Period, Weighted Average Exercise Price Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Weighted Average Exercise Price Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Aggregate Intrinsic Value, Outstanding SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueIssued SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueExercised Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Intrinsic Value SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualIssued SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualExercised SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm1 Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Weighted Average Remaining Contractual Term EX-101.PRE 11 hoth-20190630_pre.xml XBRL PRESENTATION FILE XML 12 R1.htm IDEA: XBRL DOCUMENT v3.19.2
Document and Entity Information - shares
 6 Months Ended
Jun. 30, 2019
Aug. 13, 2019
Document And Entity Information    
Entity Registrant Name Hoth Therapeutics, Inc.  
Entity Central Index Key 0001711786  
Amendment Flag false  
Current Fiscal Year End Date --12-31  
Document Type 10-Q  
Document Period End Date Jun. 30, 2019  
Document Fiscal Period Focus Q2  
Document Fiscal Year Focus 2019  
Entity Current Reporting Status Yes  
Entity Filer Category Non-accelerated Filer  
Entity Ex Transition Period false  
Entity Small Business true  
Entity Shell Company false  
Entity Emerging Growth Company true  
Entity Common Stock, Shares Outstanding   9,669,644
Entity File Number 001-38803  
Entity Incorporation State Country Code NV  
Entity Interactive Data Current Yes  
XML 13 R2.htm IDEA: XBRL DOCUMENT v3.19.2
Condensed Balance Sheets - USD ($)
Jun. 30, 2019
Dec. 31, 2018
Current assets    
Cash $ 4,092,706 $ 282,621
Prepaid expenses 101,320 12,356
Deferred offering cost 32,127 206,671
Total current assets 4,226,153 501,648
Property and equipment, net 1,660 2,268
Restricted cash 200,000
Total assets 4,427,813 503,916
Current liabilities    
Accounts payable 212,266 142,280
Accrued expenses 27,127 206,671
Total current liabilities 239,393 348,951
Total liabilities 239,393 348,951
Commitments and contingencies
Stockholders' equity    
Preferred stock value
Common stock, 0.0001 par value, 75,000,000 shares authorized at June 30, 2019 and December 31, 2018; 9,668,256 and 5,071,400 shares issued and outstanding at June 30, 2019 and December 31, 2018, respectively 967 507
Additional paid-in-capital 10,795,410 4,665,154
Accumulated deficit (6,607,957) (4,511,006)
Total stockholders' equity 4,188,420 154,965
Total liabilities and stockholders' equity 4,427,813 503,916
Series A Preferred Stock    
Stockholders' equity    
Preferred stock value $ 310
XML 14 R3.htm IDEA: XBRL DOCUMENT v3.19.2
Condensed Balance Sheets (Parenthetical) - $ / shares
Jun. 30, 2019
Dec. 31, 2018
Preferred stock, par value $ 0.0001 $ 0.0001
Preferred stock, shares authorized 5,000,000 5,000,000
Preferred stock, shares issued 0 0
Preferred stock, shares outstanding 0 0
Common stock, par value $ 0.0001 $ 0.0001
Common stock, shares authorized 75,000,000 75,000,000
Common stock, shares issued 9,668,256 5,071,400
Common stock, shares outstanding 9,668,256 5,071,400
Series A Preferred Stock    
Preferred stock, par value $ 0.0001 $ 0.0001
Preferred stock, shares authorized 5,000,000 5,000,000
Preferred stock, shares issued 0 3,102,480
Preferred stock, shares outstanding 0 3,102,480
XML 15 R4.htm IDEA: XBRL DOCUMENT v3.19.2
Condensed Statements of Operations (Unaudited) - USD ($)
 3 Months Ended 6 Months Ended
Jun. 30, 2019
Jun. 30, 2018
Jun. 30, 2019
Jun. 30, 2018
Operating costs and expenses        
Research and development $ 388,934 $ 216,667 $ 523,684 $ 257,907
Research and development - license acquired 10,000 32,028 20,000 164,192
Compensation and related expenses (including stock-based compensation) 133,486 210,453 454,935 319,482
Professional fees 544,849 229,899 838,364 422,159
Rent 8,234 6,300 15,263 12,439
Other expenses 182,083 68,073 244,705 114,787
Total operating expenses 1,267,586 763,420 2,096,951 1,290,966
Loss from operations (1,267,586) (763,420) (2,096,951) (1,290,966)
Net loss $ (1,267,586) $ (763,420) $ (2,096,951) $ (1,290,966)
Weighted average number of common shares outstanding, basic and diluted 9,603,134 5,039,800 8,312,327 4,986,306
Net loss per share, basic and diluted $ (0.13) $ (0.15) $ (0.25) $ (0.26)
XML 16 R5.htm IDEA: XBRL DOCUMENT v3.19.2
Condensed Statements of Changes in Stockholders' Equity (Unaudited) - USD ($)
Convertible Preferred Stock
Common Stock
Additional Paid-In Capital
Accumulated Deficit
Total
Balance at Dec. 31, 2017 $ 173 $ 470 $ 3,199,304 $ (2,015,481) $ 1,184,466
Balance, shares at Dec. 31, 2017 1,725,980 4,706,277      
Stock-based compensation $ 14 132,486 132,500
Stock-based compensation, shares 142,500      
Stock issued for research and development $ 3 23,497 23,500
Stock issued for research and development, shares   25,000      
Stock issued for acquired license $ 21 132,143 132,164
Stock issued for acquired license, shares 213,166      
Issuance of Series A Convertible Preferred Stock and warrants for cash in an offering (net of offering costs of 190,180) $ 137 1,021,417 1,021,554
Issuance of Series A Convertible Preferred Stock and warrants for cash in an offering (net of offering costs of 190,180), shares 1,376,500        
Warrant value related to Issuance of Series A Convertible Preferred Stock 164,767 164,767
Net loss (1,290,966) (1,290,966)
Balance at Jun. 30, 2018 $ 310 $ 508 4,673,614 (3,306,447) 1,367,985
Balance, shares at Jun. 30, 2018 3,102,480 5,086,943      
Balance at Mar. 31, 2018 $ 310 $ 496 4,543,626 (2,543,027) 2,001,405
Balance, shares at Mar. 31, 2018 3,102,480 4,956,943      
Stock-based compensation $ 11 117,489 117,500
Stock-based compensation, shares 117,500      
Stock issued for research and development $ 1 12,499 12,500
Stock issued for research and development, shares 12,500      
Net loss (763,420) (763,420)
Balance at Jun. 30, 2018 $ 310 $ 508 4,673,614 (3,306,447) 1,367,985
Balance, shares at Jun. 30, 2018 3,102,480 5,086,943      
Balance at Dec. 31, 2018 $ 310 $ 507 4,665,154 (4,511,006) 154,965
Balance, shares at Dec. 31, 2018 3,102,480 5,071,400      
Conversion of Preferred stock to common stock upon completion of the IPO $ (310) $ 310
Conversion of Preferred stock to common stock upon completion of the IPO, shares (3,102,480) 3,102,480      
Issuance common stock in the IPO, net of offering cost $ 126 5,840,042 5,840,168
Issuance common stock in the IPO, net of offering cost, shares 1,250,000      
Cashless warrant exercise $ 22 (22)
Cashless warrant exercise, shares 223,877      
Warrant exercise   $ 2 161 163
Warrant exercise, shares   16,333      
Stock-based compensation 290,075 290,075
Stock-based compensation, shares 4,166      
Net loss (2,096,951) (2,096,951)
Balance at Jun. 30, 2019 $ 967 10,795,410 (6,607,957) 4,188,420
Balance, shares at Jun. 30, 2019 9,668,256      
Balance at Mar. 31, 2019 $ 943 10,707,905 (5,340,371) 5,368,477
Balance, shares at Mar. 31, 2019 9,425,964      
Cashless warrant exercise $ 22 (22)
Cashless warrant exercise, shares 223,877      
Warrant exercise $ 2 161 163
Warrant exercise, shares 16,333      
Stock-based compensation 87,366 87,366
Stock-based compensation, shares 2,082      
Net loss (1,267,586) (1,267,586)
Balance at Jun. 30, 2019 $ 967 $ 10,795,410 $ (6,607,957) $ 4,188,420
Balance, shares at Jun. 30, 2019 9,668,256      
XML 17 R6.htm IDEA: XBRL DOCUMENT v3.19.2
Condensed Statements of Changes in Stockholders' Equity (Unaudited) (Parenthetical)
 6 Months Ended
Jun. 30, 2018
USD ($)
Statement of Stockholders' Equity [Abstract]  
Net of offering costs $ 190,180
XML 18 R7.htm IDEA: XBRL DOCUMENT v3.19.2
Condensed Statements of Cash Flows (Unaudited) - USD ($)
 6 Months Ended
Jun. 30, 2019
Jun. 30, 2018
Cash flows from operating activities    
Net loss $ (2,096,951) $ (1,290,966)
Adjustments to reconcile net loss to net cash used in operating activities:    
Depreciation expense 608 607
Research and development-acquired license, expensed 20,000 132,164
Stock issued for research and development 23,500
Stock-based compensation 290,075 132,500
Changes in assets and liabilities:    
Prepaid expenses (88,964) (27,184)
Accrued salaries and benefits (1,542)
Accounts payable 64,986 80,984
Net cash used in operating activities (1,810,246) (949,937)
Cash flows from investing activities    
Purchase of research and development licenses (20,000)
Net cash used in investing activities (20,000)
Cash flows from financing activities    
Proceeds from issuance of Series A Convertible Preferred Stock and warrants for cash in an offering, net 1,186,321
Cash from issuance of common stock in the IPO, net of offering cost 5,840,168
Proceeds from exercise of warrants 163
Net cash provided by financing activities 5,840,331 1,186,321
Net increase in cash 4,010,085 236,384
Cash and restricted cash, beginning of period 282,621 1,230,440
Cash and restricted cash, end of period 4,292,706 1,466,824
Non-cash investing and financing activities    
Conversion of preferred stock to common stock upon completion of the IPO 310
Common stock issued for acquired license   132,164
Cashless warrant exercise 22
Unpaid offering cost included in accrued expenses $ 27,127
XML 19 R8.htm IDEA: XBRL DOCUMENT v3.19.2
Organization and Description of Business Operations
 6 Months Ended
Jun. 30, 2019
Organization, Consolidation and Presentation of Financial Statements [Abstract]  
Organization and description of business operations

Note 1-Organization and description of business operations

 

Hoth Therapeutics, Inc. (the "Company") was incorporated under the laws of the State of Nevada on May 16, 2017. The Company's primary asset is a sublicense agreement with Chelexa Biosciences, Inc. ("Chelexa") pursuant to which Chelexa has granted the Company an exclusive sublicense to use its BioLexa Platform, a proprietary, patented, drug compound platform developed at the University of Cincinnati. The license enables the Company to develop the platform for all indications in humans. The Company's initial focus will be on the treatment of eczema. The BioLexa Platform combines a U.S. Food and Drug Administration ("FDA") approved zinc chelator with one or more approved antibiotics in a topical dosage form to address unchecked eczema flare-ups by preventing the formation of infectious biofilms and the resulting clogging of sweat ducts which trigger symptoms. To the Company's knowledge, it is the first product candidate intended to prevent the symptom triggering flare-ups rather than simply treating symptoms when they occur.

 

On May 26, 2017, the Company entered into a sublicense agreement with Chelexa, as amended on August 22, 2018 and August 29, 2018, pursuant to which Chelexa granted the Company an exclusive sublicense to make, use, have made, import, offer for sale, and sell products based upon or involving the use of (i) topical compositions comprising a zinc chelator and gentamicin and (ii) zinc chelators to inhibit biofilm formation (the "BioLexa Platform" or "BioLexa"), which rights were originally granted to Chelexa pursuant to an exclusive license agreement with the University of Cincinnati. In addition, Chelexa granted the Company the right to issue exclusive and nonexclusive sublicenses (with the right to further sublicense to third parties) to make, use, have made, import, offer for sale, and sell products based upon the BioLexa Platform.

 

Company's IPO

 

On February 15, 2019, the Company announced the pricing of its initial public offering (the "IPO") of 1,250,000 shares of its common stock at an initial offering price to the public of $5.60 per share.  In addition, the Company granted the underwriters a 45-day option to purchase up to an additional 187,500 shares of common stock at the initial public offering price, less the underwriting discount, to cover over-allotments (the "Green-shoe"), if any. The underwriters did not exercise any portion of the Green-shoe. Therefore, the Company issued 1,250,000 shares of common stock and received net proceeds of $5.8 million from the IPO.

 

The Company's common stock commenced trading on The Nasdaq Capital Market, on February 15, 2019 under the ticker symbol "HOTH". The IPO closed on February 20, 2019.

 

On February 14, 2019, the Company entered into an underwriting agreement with Laidlaw & Co. (UK) Ltd. ("Laidlaw") pursuant to which the Company paid Laidlaw a fee in the amount of 7% of the gross proceeds of the IPO, or $490,000. The Company also reimbursed Laidlaw for certain out-of-pocket expenses, including the fees and disbursements of their counsel, up to an aggregate of $0.2 million. In addition, Laidlaw received five-year warrants to purchase 50,000 shares of common stock of the Company at an exercise price of $7.00 per share.

 

Liquidity and capital resources

 

Accounting Standards Update, or ASU, No. 2014-15, Presentation of Financial Statements - Going Concern, requires management to evaluate the Company's ability to continue as a going concern one year beyond the filing date of the given financial statements. This evaluation requires management to perform two steps. First, management must evaluate whether there are conditions and events that raise substantial doubt about the entity's ability to continue as a going concern. Second, if management concludes that substantial doubt is raised, management is required to consider whether it has plans in place to alleviate that doubt. Disclosures in the notes to the financial statements are required if management concludes that substantial doubt exists or that its plans alleviate the substantial doubt that was raised.

 

The Company has incurred substantial operating losses since inception and expects to continue to incur significant operating losses for the foreseeable future and may never become profitable. As of June 30, 2019, the Company had cash of approximately $4.1 million, working capital of approximately $4.0 million and an accumulated deficit of approximately $6.6 million.

 

The Company has funded its operations from proceeds from the sale of equity and debt securities. The Company will require significant additional capital to make the investments it needs to execute its longer-term business plan. The Company's ability to successfully raise sufficient funds through the sale of debt or equity securities when needed is subject to many risks and uncertainties and, even if it were successful, future equity issuances would result in dilution to its existing stockholders and any future debt securities may contain covenants that limit the Company's operations or ability to enter into certain transactions.

 

The proceeds from the IPO and the current cash are sufficient to fund operations for at least the next 12 months; however, the Company will need to raise additional funding through strategic relationships, public or private equity or debt financings, grants or other arrangements to develop and seek regulatory approvals for the Company's existing and new product candidates. If such funding is not available, or not available on terms acceptable to the Company, the Company's current development plan and plans for expansion of its general and administrative infrastructure may be curtailed.
XML 20 R9.htm IDEA: XBRL DOCUMENT v3.19.2
Significant Accounting Policies
 6 Months Ended
Jun. 30, 2019
Accounting Policies [Abstract]  
Significant accounting policies

Note 2-Significant accounting policies

 

Basis of presentation

 

The accompanying unaudited interim condensed financial statements have been prepared in accordance with generally accepted accounting principles in the United States of America (“GAAP”) for interim financial information and the instructions to Form 10-Q and Article 8 of Regulation S-X. Accordingly, they do not include all of the information and footnotes required by GAAP for complete financial statements. In the opinion of management, the unaudited interim condensed financial statements reflect all adjustments, which include only normal recurring adjustments necessary for the fair statement of the balances and results for the periods presented. Certain information and footnote disclosures normally included in the Company’s annual financial statements prepared in accordance with GAAP have been condensed or omitted. These condensed financial statement results are not necessarily indicative of results to be expected for the full fiscal year or any future period. The accompanying unaudited condensed financial statements should be read in conjunction with the audited financial statements and notes thereto included in the Company’s Annual Report on Form 10-K filed by the Company with the SEC on April 1, 2019.

 

Use of estimates

 

The preparation of financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of expenses during the reporting periods. The most significant estimates in the Company’s financial statements relate to the valuation of preferred and common stock, stock-based compensation and the valuation allowance of deferred tax assets resulting from net operating losses. These estimates and assumptions are based on current facts, historical experience and various other factors believed to be reasonable under the circumstances, the results of which form the basis for making judgments about the carrying values of assets and liabilities and the recording of expenses that are not readily apparent from other sources. Actual results may differ materially and adversely from these estimates. To the extent there are material differences between the estimates and actual results, the Company’s future results of operations will be affected.

 

Significant Accounting Policies 

 

There have been no material changes to the Company’s significant accounting policies previously disclosed in the Company’s Annual Report on Form 10-K for the fiscal year ended December 31, 2018 as filed with the Securities and Exchange Commission (“SEC”) on April 1, 2019.

 

Restricted Cash

 

In November 2016, the Financial Accounting Standards Board (“FASB”) issued Accounting Standards Update (“ASU”) No. 2016-18, Statement of Cash Flows (Topic 230): Restricted Cash (“ASU 2016-18”), which clarifies the presentation of restricted cash in the statements of cash flows. Under ASU 2016-18, restricted cash is included with cash and cash equivalents when reconciling the beginning-of-period and end-of-period total amounts shown on the statements of cash flows. The Company adopted ASU 2016-18 during the six months ended June 30, 2019 on a retrospective basis. The following is a summary of the Company’s cash and restricted cash total as presented in the consolidated statements of cash flows for the six months ended June 30, 2019:

  

Cash  $4,092,706 
Restricted cash   200,000 
Total cash and restricted cash  $4,292,706 

 

The $0.2 million restricted cash has been deposited into a third-party escrow account in order to provide a source of funding for certain indemnification obligations the Company has pursuant to its Qualified Independent Underwriter Engagement Agreement.

 

Stock-based compensation

 

The Company expenses stock-based compensation to employees and non-employees over the requisite service period based on the estimated grant-date fair value of the awards. Stock-based awards with graded-vesting schedules are recognized on a straight-line basis over the requisite service period for each separately vesting portion of the award. The Company records the expense for stock-based compensation awards subject to performance-based milestone vesting over the remaining service period when management determines that achievement of the milestone is probable. Management evaluates when the achievement of a performance-based milestone is probable based on the expected satisfaction of the performance conditions at each reporting date. All stock-based compensation costs are recorded in general and administrative or research and development costs in the statements of operations based upon the underlying employees’ or non-employees’ roles within the Company.

  

Net loss per share

 

Net loss per share is computed by dividing net loss by the weighted average number of common stock outstanding during the period. Since the Company had a net loss in the periods presented, basic and diluted net loss per common share are the same. The following were excluded from the computation of diluted shares outstanding due to the losses for each period presented, as they would have had an anti-dilutive impact on the Company’s net loss:

  

   As of June 30 
Potentially dilutive securities  2019   2018 
Series A Convertible Preferred Stock (Common Stock Equivalent)   -    3,102,480 
Warrants   767,870    991,367 
Non-vested restricted stock units   17,364    - 
Total   785,234    4,093,847 

 

Recent accounting pronouncements

 

In February 2016, the FASB issued ASU No. 2016-02, Leases (Topic 842), which supersedes FASB Accounting Standards Codification (“ASC”) Topic 840, Leases (Topic 840) and provides principles for the recognition, measurement, presentation and disclosure of leases for both lessees and lessors. The new standard requires lessees to apply a dual approach, classifying leases as either finance or operating leases based on the principle of whether or not the lease is effectively a financed purchase by the lessee. This classification will determine whether lease expense is recognized based on an effective interest method or on a straight-line basis over the term of the lease. A lessee is also required to record a right-of-use asset and a lease liability for all leases with a term of greater than twelve months regardless of classification. Leases with a term of twelve months or less will be accounted for similar to existing guidance for operating leases. The standard is effective for annual and interim periods beginning after December 15, 2018, with early adoption permitted upon issuance. The Company does not have any long-term leases, therefore the adoption of this standard on January 1, 2019 did not have an impact on the Company’s condensed financial position and results of operations.

 

In June 2018, the FASB issued ASU 2018-07, Compensation—Stock Compensation (Topic 718): Improvements to Non-employee Share-Based Payment Accounting (“ASU 2018-07”). ASU 2018-07 simplifies several aspects of the accounting for non-employee share-based payment transactions resulting from expanding the scope of Topic 718, Compensation—Stock Compensation, to include share-based payment transactions for acquiring goods and services from non-employees. ASU 2018-07 is effective for public business entities for fiscal years beginning after December 15, 2018, including interim periods within that fiscal year. The Company adopted ASU 2018-07 on January 1, 2019.  Subsequent to the adoption of ASU 2018-07, the Company recognizes non-employee compensation costs over the requisite service period based on a measurement of fair value for each stock award.

 

Management does not believe that any other recently issued, but not yet effective accounting pronouncements, if currently adopted, would have an effect on the Company’s financial statements.
XML 21 R10.htm IDEA: XBRL DOCUMENT v3.19.2
License Agreements
 6 Months Ended
Jun. 30, 2019
License Agreement [Abstract]  
License agreements

Note 3 - License agreements

 

Chelexa BioSciences, Inc.

 

On May 26, 2017, the Company entered into a sublicense agreement with  Chelexa BioSciences, Inc. (“Chelexa”) as amended on August 22, 2018 and August 29, 2018. The term of such agreement will expire on the later of April 16, 2034 and the last to expire patent in the patent rights granted to the Company (the “Term”). The Company shall, in its sole discretion, have the first right of refusal to renew the Term. The Company is subject to total milestone payments of $3.5 million and has agreed to fund all development and commercialization costs related to the licensed products. In addition, during the Term, the Company shall pay royalty payments which shall be based on a percentage of annual aggregate net sales.

 

University of Maryland and Isoprene Pharmaceuticals, Inc.

 

On March 8, 2019, the Company, the University of Maryland, Baltimore (“UMD”) and Isoprene Pharmaceuticals, Inc. (“Isoprene”) entered into a commercial evaluation sublicense and option agreement. In consideration of the rights granted under the agreement, the Company paid an initial option and material access fee of $5,000 to UMD and $5,000 to Isoprene. In the event that Isoprene enters into a master license agreement with UMD (the “MLA”), UMD shall permit Isoprene to grant an exclusive option to the Company to negotiate and obtain an exclusive sublicensable, worldwide royalty-bearing license to the subject technology (the “Isoprene-Hoth Option”); provided, however, in the event Isoprene does not enter into the MLA, UMD may grant the Company an option to negotiate and obtain an exclusive sublicensable, worldwide royalty-bearing license to the subject technology (the “UMD-Hoth Option”). If the Company exercises the Isoprene-Hoth Option, it shall pay Isoprene an option exercise fee of $20,000. If the Company exercises the UMD-Hoth Option, it shall pay UMD an option exercise fee of $20,000.

 

Zylö Therapeutics Inc.

 

On May 10, 2019, the Company and Zylö Therapeutics Inc. (“Zylö”) entered into a term sheet (the “Zylö Term Sheet”) with respect to the potential development and commercialization of certain licensed products. As of June 30, 2019, the Company paid Zylö $10,000 upon execution of the Zylö Term Sheet.
XML 22 R11.htm IDEA: XBRL DOCUMENT v3.19.2
Stockholders' Equity
 6 Months Ended
Jun. 30, 2019
Equity [Abstract]  
Stockholders' Equity

Note 4-Stockholders’ Equity 

 

Preferred Stock

 

The Company is authorized to issue up to 10,000,000 shares of preferred stock. This preferred stock may be issued in one or more series, and shall have such designations, preferences and relative, participating, optional or other special rights and qualifications, limitations or restrictions thereof as shall be determined at the time of issuance by its board of directors without further action by shareholders. As of June 30, 2019, 5,000,000 shares of the Company’s preferred stock has been designated as Series A Preferred Stock. At the time of the IPO, 3,102,480 shares of Series A Preferred Stock which were previously issued were converted into common stock and 1,897,520 shares of Series A Preferred Stock remained authorized.

 

Common Shares

 

On February 15, 2019, the Company announced the pricing of its initial public offering of 1,250,000 shares of its common stock at an initial offering price to the public of $5.60 per share. The Company issued an aggregate of 1,250,000 shares of common stock and received net proceeds of $5.8 million from the IPO.

 

Restricted Stock Awards

 

A summary of the Company’s restricted stock awards activities under the Company’s 2018 Equity Incentive Plan (the “2018 Plan”) during the six months ended June 30, 2019 is as follows:

  

   Number of Units   Weighted Average
Grant Day
Fair Value		 
Nonvested at May 16, 2017 (inception)   -   $- 
Nonvested at December 31, 2017   -    - 
Granted   37,500    0.25 
Vested   (15,970)   0.25 
Nonvested at December 31, 2018   21,530   $0.25 
Vested   (4,166)  $0.25 
Nonvested at June 30, 2019   17,364   $0.25 

 

As of June 30, 2019, the Company had approximately $8,000 of unrecognized stock-based compensation expense which was related to restricted stock awards. The weighted average remaining contractual terms of unvested restricted stock awards is approximately 1.01 years at June 30, 2019.

 

Stock Options

 

On March 6, 2019, the Company granted 50,000 options to purchase common stock of the Company to its CFO pursuant to the 2018 Plan. The aggregate grant date fair value of these options was approximately $0.2 million. The stock options vested in full upon grant.

 

Warrants

 

A summary of warrant activity for the six months ended June 30, 2019 is presented below:

  

   Number of
Warrants		   Weighted Average
Exercise Price		   Total
Intrinsic
Value		   Weighted Average Remaining Contractual Life (in years) 
Outstanding as of December 31, 2018   991,367   $1.00   $-    5.4 
Issued   66,333    5.28    94,731    4.9 
Exercised   (289,830)   0.94    -    - 
Outstanding as of June 30, 2019   767,870   $1.39   $3,452,955    5.6 
Warrants exercisable as of June 30, 2019   767,870   $1.39   $3,452,955    5.6 

 

On February 20, 2019, Laidlaw received five-year warrants to purchase 50,000 shares of the Company’s common stock at an exercise price of $7.00 per share. These warrants are not exercisable prior to August 13, 2019.

  

On April 17, 2019, the Company entered into a Master Service Agreement (the “MSA”) with a consultant (the “Consultant”). In consideration for services provided by the Consultant, the Company issued the Consultant a two year warrant to purchase up to 50,000 shares of the Company’s common stock at an exercise price of $0.01 per share (the “Consultant Warrant”). On May 22, 2019, the Company and Consultant agreed to terminate the MSA and number of shares of the Company’s common stock issuable upon exercise of the Consultant Warrant was reduced to 16,333. On June 27, 2019, the Company issued 16,333 shares of common stock upon exercise of the Consultant Warrant which resulted in gross proceeds of approximately $163.

 

On April 16, 2019, the Company issued 176,272 shares of common stock upon the cashless exercise of warrants to purchase up to 215,747 shares of common stock. Those warrants were issued by the Company to Laidlaw pursuant to the terms of its engagement letter with Laidlaw with respect to the private placement of its securities through October 2017 to December 2017.

 

On June 6, 2019, the Company issued 47,605 shares of common stock upon the cashless exercise of warrants to purchase up to 57,750 shares of common stock.

 

The Company has determined that the warrants should be accounted as a component of stockholders’ equity.

 

Stock Based Compensation

 

Stock-based compensation expense for the three and six months ended June 30, 2019 and 2018 was as follows:

  

   For the Three Months Ended
June 30,		   For the Six Months Ended
June 30,		 
   2019   2018   2019   2018 
Employee common stock awards  $-   $117,500   $-   $132,500 
Employee stock option awards   -    -    199,182    - 
Employee restricted stock awards   2,761    -    6,289    - 
Non-employee warrant awards   84,605         84,605      
   $87,366   $117,500   $290,075   $132,500 

 

In addition, the Company recorded $0 and $13,000 of stock issued for research and development services for the three months ended June 30, 2019 and 2018, respectively, and $0 and $24,000 of stock issued for research and development services for the six months ended June 30, 2019 and 2018, respectively.

 

Employee related stock based compensation is recognized as “compensation and related expenses” and non-employee related stock based compensation is recognized as “professional fees” in the condensed statements of operations.
XML 23 R12.htm IDEA: XBRL DOCUMENT v3.19.2
Commitments and Contingencies
 6 Months Ended
Jun. 30, 2019
Commitments and Contingencies Disclosure [Abstract]  
Commitments and contingencies

Note 5-Commitments and contingencies

 

Office lease

 

The Company leases office space that commenced on July 15, 2017, for approximately $2,000 a month. Rent expense for the six months ended June 30, 2019 and 2018 was approximately $15,000 and $12,000, respectively. The term of the lease expires on July 31, 2020. In accordance with ASC 842, this lease meets the definition of a short-term lease and accordingly, is not subject to capitalization.

 

Litigation

 

The Company is not a party to any material legal proceedings and is not aware of any pending or threatened claims. From time to time, the Company may be subject to various legal proceedings and claims that arise in the ordinary course of its business activities.
XML 24 R13.htm IDEA: XBRL DOCUMENT v3.19.2
Significant Accounting Policies (Policies)
 6 Months Ended
Jun. 30, 2019
Accounting Policies [Abstract]  
Basis of presentation

Basis of presentation

 

The accompanying unaudited interim condensed financial statements have been prepared in accordance with generally accepted accounting principles in the United States of America ("GAAP") for interim financial information and the instructions to Form 10-Q and Article 8 of Regulation S-X. Accordingly, they do not include all of the information and footnotes required by GAAP for complete financial statements. In the opinion of management, the unaudited interim condensed financial statements reflect all adjustments, which include only normal recurring adjustments necessary for the fair statement of the balances and results for the periods presented. Certain information and footnote disclosures normally included in the Company's annual financial statements prepared in accordance with GAAP have been condensed or omitted. These condensed financial statement results are not necessarily indicative of results to be expected for the full fiscal year or any future period. The accompanying unaudited condensed financial statements should be read in conjunction with the audited financial statements and notes thereto included in the Company's Annual Report on Form 10-K filed by the Company with the SEC on April 1, 2019.
Use of estimates

Use of estimates

 

The preparation of financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of expenses during the reporting periods. The most significant estimates in the Company's financial statements relate to the valuation of preferred and common stock, stock-based compensation and the valuation allowance of deferred tax assets resulting from net operating losses. These estimates and assumptions are based on current facts, historical experience and various other factors believed to be reasonable under the circumstances, the results of which form the basis for making judgments about the carrying values of assets and liabilities and the recording of expenses that are not readily apparent from other sources. Actual results may differ materially and adversely from these estimates. To the extent there are material differences between the estimates and actual results, the Company's future results of operations will be affected.
Significant Accounting Policies

Significant Accounting Policies 

 

There have been no material changes to the Company's significant accounting policies previously disclosed in the Company's Annual Report on Form 10-K for the fiscal year ended December 31, 2018 as filed with the Securities and Exchange Commission ("SEC") on April 1, 2019.
Restricted Cash

Restricted Cash

 

In November 2016, the Financial Accounting Standards Board (“FASB”) issued Accounting Standards Update (“ASU”) No. 2016-18, Statement of Cash Flows (Topic 230): Restricted Cash (“ASU 2016-18”), which clarifies the presentation of restricted cash in the statements of cash flows. Under ASU 2016-18, restricted cash is included with cash and cash equivalents when reconciling the beginning-of-period and end-of-period total amounts shown on the statements of cash flows. The Company adopted ASU 2016-18 during the six months ended June 30, 2019 on a retrospective basis. The following is a summary of the Company’s cash and restricted cash total as presented in the consolidated statements of cash flows for the six months ended June 30, 2019:

  

Cash  $4,092,706 
Restricted cash   200,000 
Total cash and restricted cash  $4,292,706 

 

The $0.2 million restricted cash has been deposited into a third-party escrow account in order to provide a source of funding for certain indemnification obligations the Company has pursuant to its Qualified Independent Underwriter Engagement Agreement.
Stock-based compensation

Stock-based compensation

 

The Company expenses stock-based compensation to employees and non-employees over the requisite service period based on the estimated grant-date fair value of the awards. Stock-based awards with graded-vesting schedules are recognized on a straight-line basis over the requisite service period for each separately vesting portion of the award. The Company records the expense for stock-based compensation awards subject to performance-based milestone vesting over the remaining service period when management determines that achievement of the milestone is probable. Management evaluates when the achievement of a performance-based milestone is probable based on the expected satisfaction of the performance conditions at each reporting date. All stock-based compensation costs are recorded in general and administrative or research and development costs in the statements of operations based upon the underlying employees' or non-employees' roles within the Company.
Net loss per share

Net loss per share

 

Net loss per share is computed by dividing net loss by the weighted average number of common stock outstanding during the period. Since the Company had a net loss in the periods presented, basic and diluted net loss per common share are the same. The following were excluded from the computation of diluted shares outstanding due to the losses for each period presented, as they would have had an anti-dilutive impact on the Company's net loss:

  

   As of June 30 
Potentially dilutive securities  2019   2018 
Series A Convertible Preferred Stock (Common Stock Equivalent)   -    3,102,480 
Warrants   767,870    991,367 
Non-vested restricted stock units   17,364    - 
Total   785,234    4,093,847 
Recent accounting pronouncements

Recent accounting pronouncements

 

In February 2016, the FASB issued ASU No. 2016-02, Leases (Topic 842), which supersedes FASB Accounting Standards Codification ("ASC") Topic 840, Leases (Topic 840) and provides principles for the recognition, measurement, presentation and disclosure of leases for both lessees and lessors. The new standard requires lessees to apply a dual approach, classifying leases as either finance or operating leases based on the principle of whether or not the lease is effectively a financed purchase by the lessee. This classification will determine whether lease expense is recognized based on an effective interest method or on a straight-line basis over the term of the lease. A lessee is also required to record a right-of-use asset and a lease liability for all leases with a term of greater than twelve months regardless of classification. Leases with a term of twelve months or less will be accounted for similar to existing guidance for operating leases. The standard is effective for annual and interim periods beginning after December 15, 2018, with early adoption permitted upon issuance. The Company does not have any long-term leases, therefore the adoption of this standard on January 1, 2019 did not have an impact on the Company's condensed financial position and results of operations.

 

In June 2018, the FASB issued ASU 2018-07, Compensation—Stock Compensation (Topic 718): Improvements to Non-employee Share-Based Payment Accounting ("ASU 2018-07"). ASU 2018-07 simplifies several aspects of the accounting for non-employee share-based payment transactions resulting from expanding the scope of Topic 718, Compensation—Stock Compensation, to include share-based payment transactions for acquiring goods and services from non-employees. ASU 2018-07 is effective for public business entities for fiscal years beginning after December 15, 2018, including interim periods within that fiscal year. The Company adopted ASU 2018-07 on January 1, 2019.  Subsequent to the adoption of ASU 2018-07, the Company recognizes non-employee compensation costs over the requisite service period based on a measurement of fair value for each stock award.

 

Management does not believe that any other recently issued, but not yet effective accounting pronouncements, if currently adopted, would have an effect on the Company's financial statements.
XML 25 R14.htm IDEA: XBRL DOCUMENT v3.19.2
Significant Accounting Policies (Tables)
 6 Months Ended
Jun. 30, 2019
Accounting Policies [Abstract]  
Schedule of consolidated statements of cash flows

  

Cash  $4,092,706 
Restricted cash   200,000 
Total cash and restricted cash  $4,292,706 
Schedule of anti-dilutive impact on net loss

   As of June 30 
Potentially dilutive securities  2019   2018 
Series A Convertible Preferred Stock (Common Stock Equivalent)   -    3,102,480 
Warrants   767,870    991,367 
Non-vested restricted stock units   17,364    - 
Total   785,234    4,093,847 
XML 26 R15.htm IDEA: XBRL DOCUMENT v3.19.2
Stockholders' Equity (Tables)
 6 Months Ended
Jun. 30, 2019
Equity [Abstract]  
restricted stock awards activities under the Company's 2018 Equity Incentive Plan

   Number of Units   Weighted Average
Grant Day
Fair Value		 
Nonvested at May 16, 2017 (inception)   -   $- 
Nonvested at December 31, 2017   -    - 
Granted   37,500    0.25 
Vested   (15,970)   0.25 
Nonvested at December 31, 2018   21,530   $0.25 
Vested   (4,166)  $0.25 
Nonvested at June 30, 2019   17,364   $0.25
Schedule of warrant activity

   Number of
Warrants		   Weighted Average
Exercise Price		   Total
Intrinsic
Value		   Weighted Average Remaining Contractual Life (in years) 
Outstanding as of December 31, 2018   991,367   $1.00   $-    5.4 
Issued   66,333    5.28    94,731    4.9 
Exercised   (289,830)   0.94    -    - 
Outstanding as of June 30, 2019   767,870   $1.39   $3,452,955    5.6 
Warrants exercisable as of June 30, 2019   767,870   $1.39   $3,452,955    5.6
Schedule of Stock-based compensation expense

   For the Three Months Ended
June 30,		   For the Six Months Ended
June 30,		 
   2019   2018   2019   2018 
Employee common stock awards  $-   $117,500   $-   $132,500 
Employee stock option awards   -    -    199,182    - 
Employee restricted stock awards   2,761    -    6,289    - 
Non-employee warrant awards   84,605         84,605      
   $87,366   $117,500   $290,075   $132,500 
XML 27 R16.htm IDEA: XBRL DOCUMENT v3.19.2
Organization and Description of Business Operations (Details) - USD ($)
 1 Months Ended
Feb. 15, 2019
Feb. 14, 2019
Jun. 30, 2019
Dec. 31, 2018
Organization and Description of Business Operations (Textual)        
Cash     $ 4,100,000  
Working capital     4,000,000  
Accumulated deficit     $ (6,607,957) $ (4,511,006)
Initial public offering [Member]        
Organization and Description of Business Operations (Textual)        
Common stock issued for initial public offering price 1,250,000      
Additional shares of common stock 187,500      
Net proceeds from initial public offering $ 5,800,000      
Initial offering price per share $ 5.60      
Description of underwriting agreement   The Company entered into an underwriting agreement with Laidlaw & Co. (UK) Ltd. ("Laidlaw") pursuant to which the Company paid Laidlaw a fee in the amount of 7% of the gross proceeds of the IPO, or $490,000. The Company also reimbursed Laidlaw for certain out-of-pocket expenses, including the fees and disbursements of their counsel, up to an aggregate of $0.2 million. In addition, Laidlaw received five-year warrants to purchase 50,000 shares of common stock of the Company at an exercise price of $7.00 per share.    
XML 28 R17.htm IDEA: XBRL DOCUMENT v3.19.2
Significant Accounting Policies (Details)
Jun. 30, 2019
USD ($)
Significant Accounting Policies Abstract  
Cash $ 4,092,706
Restricted cash 200,000
Total cash and restricted cash $ 4,292,706
XML 29 R18.htm IDEA: XBRL DOCUMENT v3.19.2
Significant Accounting Policies (Details 1) - shares
 6 Months Ended
Jun. 30, 2019
Jun. 30, 2018
Potentially dilutive securities    
Total 785,234 4,093,847
Series A Convertible Preferred Stock (Common Stock Equivalent) [Member]    
Potentially dilutive securities    
Total 3,102,480
Warrants [Member]    
Potentially dilutive securities    
Total 767,870 991,367
Non-vested restricted stock units [Member]    
Potentially dilutive securities    
Total 17,364
XML 30 R19.htm IDEA: XBRL DOCUMENT v3.19.2
Significant Accounting Policies (Details Textual)
Jun. 30, 2019
USD ($)
Significant Accounting Policies Abstract  
Escrow deposit $ 200,000
XML 31 R20.htm IDEA: XBRL DOCUMENT v3.19.2
License Agreements (Details) - USD ($)
 6 Months Ended
Mar. 08, 2019
Jun. 30, 2019
Commercial evaluation sublicense and option agreement description The Company, the University of Maryland, Baltimore ("UMD") and Isoprene Pharmaceuticals, Inc. ("Isoprene") entered into a commercial evaluation sublicense and option agreement. In consideration of the rights granted under the agreement, the Company paid an initial option and material access fee of $5,000 to UMD and $5,000 to Isoprene.  
Chelexa BioSciences, Inc. [Member]    
Milestone payments   $ 3,500,000
Zylö Therapeutics Inc. [Member]    
Development and commercialization expenses   10,000
Isoprene-Hoth Option [Member]    
Option exercise fee   20,000
UMD-Hoth Option [Member]    
Option exercise fee   $ 20,000
XML 32 R21.htm IDEA: XBRL DOCUMENT v3.19.2
Stockholders' Equity (Details) - Restricted Stock Awards [Member] - $ / shares
 6 Months Ended 8 Months Ended 12 Months Ended
Jun. 30, 2019
Dec. 31, 2017
Dec. 31, 2018
Number of Units      
Number of Shares, Nonvested Beginning Balance 21,530  
Number of Shares, Granted   37,500
Number of Shares, Vested (4,166)   (15,970)
Number of Shares, Nonvested Ending Balance 17,364 21,530
Weighted Average Grant Day Fair Value      
Weighted average grant day fair value, Nonvested Beginning balance $ 0.25  
Weighted average grant day fair value, Granted     0.25
Weighted average grant day fair value, Vested 0.25 0.25
Weighted average grant day fair value, Nonvested Ending balance $ 0.25 $ 0.25
XML 33 R22.htm IDEA: XBRL DOCUMENT v3.19.2
Stockholders' Equity (Details 1) - Warrants [Member]
 6 Months Ended
Jun. 30, 2019
USD ($)
$ / shares
shares
Number of Warrants  
Outstanding | shares 991,367
Issued | shares 66,333
Exercised | shares (289,830)
Outstanding | shares 767,870
Warrants exercisable | shares 767,870
Weighted Average Exercise Price  
Outstanding | $ / shares $ 1.00
Issued | $ / shares 5.28
Exercised | $ / shares 0.94
Outstanding | $ / shares 1.39
Warrants exercisable | $ / shares $ 1.39
Total Intrinsic Value  
Outstanding | $
Issued | $ 94,731
Exercised | $
Outstanding | $ 3,452,955
Warrants exercisable | $ $ 3,452,955
Weighted Average Remaining Contractual Life (in years)  
Outstanding 5 years 4 months 24 days
Issued 4 years 10 months 25 days
Exercised 0 years
Outstanding 5 years 7 months 6 days
Warrants exercisable 5 years 7 months 6 days
XML 34 R23.htm IDEA: XBRL DOCUMENT v3.19.2
Stockholders' Equity (Details 2) - USD ($)
 3 Months Ended 6 Months Ended
Jun. 30, 2019
Jun. 30, 2018
Jun. 30, 2019
Jun. 30, 2018
Stock-based compensation     $ 290,075 $ 132,500
Restricted Stock Awards [Member]        
Stock-based compensation $ 87,366 $ 117,500 290,075 132,500
Restricted Stock Awards [Member] | Employee common stock awards [Member]        
Stock-based compensation 117,500 132,500
Restricted Stock Awards [Member] | Employee stock option awards [Member]        
Stock-based compensation 199,182
Restricted Stock Awards [Member] | Employee restricted stock awards [Member]        
Stock-based compensation 2,761 6,289
Restricted Stock Awards [Member] | Non-employee warrant awards [Member]        
Stock-based compensation $ 84,605 $ 84,605
XML 35 R24.htm IDEA: XBRL DOCUMENT v3.19.2
Stockholders' Equity (Details Textual) - USD ($)
 1 Months Ended 3 Months Ended 6 Months Ended
Jun. 06, 2019
Apr. 17, 2019
Apr. 16, 2019
Mar. 06, 2019
Feb. 20, 2019
Feb. 15, 2019
Jun. 27, 2019
May 22, 2019
Jun. 30, 2019
Jun. 30, 2018
Jun. 30, 2019
Jun. 30, 2018
Dec. 31, 2018
Stockholders' Equity (Textual)                          
Warrants to purchase of common stock shares   50,000     50,000                
Warrants exercise price   $ 0.01     $ 7.00                
Unrecognized stock-based compensation expense                 $ 8,000   $ 8,000    
Weighted average remaining contractual terms of unvested restricted stock                     1 year 4 days    
Preferred stock, shares authorized                 5,000,000   5,000,000   5,000,000
Net proceeds received             $ 163            
Exercise warrant reduced             16,333 16,333          
Common stock issued, description The Company issued 47,605 shares of common stock upon the cashless exercise of warrants to purchase up to 57,750 shares of common stock.   The Company issued 176,272 shares of common stock upon the cashless exercise of warrants to purchase up to 215,747 shares of common stock. Those warrants were issued by the Company to Laidlaw pursuant to the terms of its engagement letter with Laidlaw with respect to the private placement of its securities through October 2017 to December 2017.                    
Stock issued for research and development                 $ 0 $ 13,000 $ 23,500  
2018 Equity Incentive Plan [Member]                          
Stockholders' Equity (Textual)                          
Options granted       50,000                  
Aggregate grant fair value       $ 200,000                  
Initial public offering [Member]                          
Stockholders' Equity (Textual)                          
Price per share           $ 5.60              
Issuance of shares of common stock, shares           1,250,000              
Shares of common stock           1,250,000              
Net proceeds received           $ 5,800,000              
Convertible Preferred Stock                          
Stockholders' Equity (Textual)                          
Preferred stock, shares authorized                 10,000,000   10,000,000    
Preferred stock designated                 5,000,000   5,000,000    
Preferred stock converted into common stock                 3,102,480   3,102,480    
Preferred Shares remain authorized                 1,897,520   1,897,520    
XML 36 R25.htm IDEA: XBRL DOCUMENT v3.19.2
Commitments and Contingencies (Details) - USD ($)
 6 Months Ended
Jun. 30, 2019
Jun. 30, 2018
Commitments and Contingencies (Textual)    
Lease agreement terms, description The Company leases office space that commenced on July 15, 2017, for approximately $2,000 a month.  
Rent expense $ 15,000 $ 12,000
Lease expires date Jul. 31, 2020  
EXCEL 37 Financial_Report.xlsx IDEA: XBRL DOCUMENT begin 644 Financial_Report.xlsx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end XML 38 Show.js IDEA: XBRL DOCUMENT // Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission. Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105. var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0); e.removeAttribute('id');a.parentNode.appendChild(e)}} if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'} e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}} XML 39 report.css IDEA: XBRL DOCUMENT /* Updated 2009-11-04 */ /* v2.2.0.24 */ /* DefRef Styles */ ..report table.authRefData{ background-color: #def; border: 2px solid #2F4497; font-size: 1em; position: absolute; } ..report table.authRefData a { display: block; font-weight: bold; } ..report table.authRefData p { margin-top: 0px; } ..report table.authRefData .hide { background-color: #2F4497; padding: 1px 3px 0px 0px; text-align: right; } ..report table.authRefData .hide a:hover { background-color: #2F4497; } ..report table.authRefData .body { height: 150px; overflow: auto; width: 400px; } ..report table.authRefData table{ font-size: 1em; } /* Report Styles */ ..pl a, .pl a:visited { color: black; text-decoration: none; } /* table */ ..report { background-color: white; border: 2px solid #acf; clear: both; color: black; font: normal 8pt Helvetica, Arial, san-serif; margin-bottom: 2em; } ..report hr { border: 1px solid #acf; } /* Top labels */ ..report th { background-color: #acf; color: black; font-weight: bold; text-align: center; } ..report th.void { background-color: transparent; color: #000000; font: bold 10pt Helvetica, Arial, san-serif; text-align: left; } ..report .pl { text-align: left; vertical-align: top; white-space: normal; width: 200px; white-space: normal; /* word-wrap: break-word; */ } ..report td.pl a.a { cursor: pointer; display: block; width: 200px; overflow: hidden; } ..report td.pl div.a { width: 200px; } ..report td.pl a:hover { background-color: #ffc; } /* Header rows... */ ..report tr.rh { background-color: #acf; color: black; font-weight: bold; } /* Calendars... */ ..report .rc { background-color: #f0f0f0; } /* Even rows... */ ..report .re, .report .reu { background-color: #def; } ..report .reu td { border-bottom: 1px solid black; } /* Odd rows... */ ..report .ro, .report .rou { background-color: white; } ..report .rou td { border-bottom: 1px solid black; } ..report .rou table td, .report .reu table td { border-bottom: 0px solid black; } /* styles for footnote marker */ ..report .fn { white-space: nowrap; } /* styles for numeric types */ ..report .num, .report .nump { text-align: right; white-space: nowrap; } ..report .nump { padding-left: 2em; } ..report .nump { padding: 0px 0.4em 0px 2em; } /* styles for text types */ ..report .text { text-align: left; white-space: normal; } ..report .text .big { margin-bottom: 1em; width: 17em; } ..report .text .more { display: none; } ..report .text .note { font-style: italic; font-weight: bold; } ..report .text .small { width: 10em; } ..report sup { font-style: italic; } ..report .outerFootnotes { font-size: 1em; } XML 40 FilingSummary.xml IDEA: XBRL DOCUMENT 3.19.2 html 106 245 1 false 21 0 false 3 false false R1.htm 00000001 - Document - Document and Entity Information Sheet http://hoththerapeutics.com/role/DocumentAndEntityInformation Document and Entity Information Cover 1 false false R2.htm 00000002 - Statement - Condensed Balance Sheets Sheet http://hoththerapeutics.com/role/BalanceSheets Condensed Balance Sheets Statements 2 false false R3.htm 00000003 - Statement - Condensed Balance Sheets (Parenthetical) Sheet http://hoththerapeutics.com/role/BalanceSheetsParenthetical Condensed Balance Sheets (Parenthetical) Statements 3 false false R4.htm 00000004 - Statement - Condensed Statements of Operations (Unaudited) Sheet http://hoththerapeutics.com/role/StatementsOfOperations Condensed Statements of Operations (Unaudited) Statements 4 false false R5.htm 00000005 - Statement - Condensed Statements of Changes in Stockholders' Equity (Unaudited) Sheet http://hoththerapeutics.com/role/StatementsOfChangesInStockholdersEquity Condensed Statements of Changes in Stockholders' Equity (Unaudited) Statements 5 false false R6.htm 00000006 - Statement - Condensed Statements of Changes in Stockholders' Equity (Unaudited) (Parenthetical) Sheet http://hoththerapeutics.com/role/StatementsOfChangesInStockholdersEquityParenthetical Condensed Statements of Changes in Stockholders' Equity (Unaudited) (Parenthetical) Statements 6 false false R7.htm 00000007 - Statement - Condensed Statements of Cash Flows (Unaudited) Sheet http://hoththerapeutics.com/role/StatementsOfCashFlows Condensed Statements of Cash Flows (Unaudited) Statements 7 false false R8.htm 00000008 - Disclosure - Organization and Description of Business Operations Sheet http://hoththerapeutics.com/role/OrganizationAndDescriptionOfBusinessOperations Organization and Description of Business Operations Notes 8 false false R9.htm 00000009 - Disclosure - Significant Accounting Policies Sheet http://hoththerapeutics.com/role/SignificantAccountingPolicies Significant Accounting Policies Notes 9 false false R10.htm 00000010 - Disclosure - License Agreements Sheet http://hoththerapeutics.com/role/LicenseAgreements License Agreements Notes 10 false false R11.htm 00000011 - Disclosure - Stockholders' Equity Sheet http://hoththerapeutics.com/role/StockholdersEquity Stockholders' Equity Notes 11 false false R12.htm 00000012 - Disclosure - Commitments and Contingencies Sheet http://hoththerapeutics.com/role/CommitmentsAndContingencies Commitments and Contingencies Notes 12 false false R13.htm 00000013 - Disclosure - Significant Accounting Policies (Policies) Sheet http://hoththerapeutics.com/role/SignificantAccountingPoliciesPolicies Significant Accounting Policies (Policies) Policies http://hoththerapeutics.com/role/SignificantAccountingPolicies 13 false false R14.htm 00000014 - Disclosure - Significant Accounting Policies (Tables) Sheet http://hoththerapeutics.com/role/SignificantAccountingPoliciesTables Significant Accounting Policies (Tables) Tables http://hoththerapeutics.com/role/SignificantAccountingPolicies 14 false false R15.htm 00000015 - Disclosure - Stockholders' Equity (Tables) Sheet http://hoththerapeutics.com/role/StockholdersEquityTables Stockholders' Equity (Tables) Tables http://hoththerapeutics.com/role/StockholdersEquity 15 false false R16.htm 00000016 - Disclosure - Organization and Description of Business Operations (Details) Sheet http://hoththerapeutics.com/role/OrganizationAndDescriptionOfBusinessOperationsDetails Organization and Description of Business Operations (Details) Details http://hoththerapeutics.com/role/OrganizationAndDescriptionOfBusinessOperations 16 false false R17.htm 00000017 - Disclosure - Significant Accounting Policies (Details) Sheet http://hoththerapeutics.com/role/SignificantAccountingPoliciesDetails Significant Accounting Policies (Details) Details http://hoththerapeutics.com/role/SignificantAccountingPoliciesTables 17 false false R18.htm 00000018 - Disclosure - Significant Accounting Policies (Details 1) Sheet http://hoththerapeutics.com/role/SignificantAccountingPoliciesDetails1 Significant Accounting Policies (Details 1) Details http://hoththerapeutics.com/role/SignificantAccountingPoliciesTables 18 false false R19.htm 00000019 - Disclosure - Significant Accounting Policies (Details Textual) Sheet http://hoththerapeutics.com/role/SignificantAccountingPoliciesDetailsTextual Significant Accounting Policies (Details Textual) Details http://hoththerapeutics.com/role/SignificantAccountingPoliciesTables 19 false false R20.htm 00000020 - Disclosure - License Agreements (Details) Sheet http://hoththerapeutics.com/role/LicenseAgreementsDetails License Agreements (Details) Details http://hoththerapeutics.com/role/LicenseAgreements 20 false false R21.htm 00000021 - Disclosure - Stockholders' Equity (Details) Sheet http://hoththerapeutics.com/role/StockholdersEquityDetails Stockholders' Equity (Details) Details http://hoththerapeutics.com/role/StockholdersEquityTables 21 false false R22.htm 00000022 - Disclosure - Stockholders' Equity (Details 1) Sheet http://hoththerapeutics.com/role/StockholdersEquityDetails1 Stockholders' Equity (Details 1) Details http://hoththerapeutics.com/role/StockholdersEquityTables 22 false false R23.htm 00000023 - Disclosure - Stockholders' Equity (Details 2) Sheet http://hoththerapeutics.com/role/StockholdersEquityDetails2 Stockholders' Equity (Details 2) Details http://hoththerapeutics.com/role/StockholdersEquityTables 23 false false R24.htm 00000024 - Disclosure - Stockholders' Equity (Details Textual) Sheet http://hoththerapeutics.com/role/StockholdersEquityDetailsTextual Stockholders' Equity (Details Textual) Details http://hoththerapeutics.com/role/StockholdersEquityTables 24 false false R25.htm 00000025 - Disclosure - Commitments and Contingencies (Details) Sheet http://hoththerapeutics.com/role/CommitmentsAndContingenciesDetails Commitments and Contingencies (Details) Details http://hoththerapeutics.com/role/CommitmentsAndContingencies 25 false false All Reports Book All Reports hoth-20190630.xml hoth-20190630.xsd hoth-20190630_cal.xml hoth-20190630_def.xml hoth-20190630_lab.xml hoth-20190630_pre.xml http://fasb.org/us-gaap/2019-01-31 http://fasb.org/srt/2019-01-31 http://xbrl.sec.gov/dei/2019-01-31 true true ZIP 42 0001213900-19-015804-xbrl.zip IDEA: XBRL DOCUMENT begin 644 0001213900-19-015804-xbrl.zip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end